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Exercise and Nrf2 in Chronic Heart Failure  
Ahmed Wafi, University of Nebraska Medical Center, 2020 
Supervisor: Irving H Zucker, Ph.D. 
Increased activation of the sympathetic nervous system (SNS) plays an essential 
role in the pathogenesis of cardiovascular diseases such as chronic heart failure (CHF) 
and hypertension. Oxidative stress in key brain regions that are involved in maintenance 
and regulation of sympathetic vasomotor tone has been implicated in mediating this 
sympathoexcitation. One particular mechanism of oxidative stress-mediated increases in 
SNS is a reduction of antioxidant enzymes in rostral ventrolateral medulla (RVLM) 
neurons. Nuclear factor erythroid 2 related factor 2 (Nrf2) is a master regulator of cellular 
redox homeostasis that impacts the expression of antioxidant gene expression. Recent 
studies have demonstrated that Nrf2 gene deletion in the RVLM reduces antioxidant 
enzymes and increases sympathetic outflow, whereas the upregulation of Nrf2 
selectively in the RVLM attenuates sympathoexcitation in CHF mice.  
Despite current CHF therapy that targets the renin-angiotensin and adrenergic 
systems, the morbidity and mortality of this disease are still extremely high, even with 
the best medical management. Exercise training (ExT) is now considered as adjunctive 
therapy for CHF. Growing evidence indicates that the beneficial effects of ExT in CHF 
are dependent, at least in part, on augmented central antioxidant capacity, which results 
in a reduction of sympathetic nervous activity. However, the exact mechanism by which 
ExT enhances antioxidant activity in central neurons remains unexplored. We 
hypothesized that Nrf2 plays a key role in modulating antioxidant enzymes in the RVLM 
and sympathoexcitation in the CHF state. Molecular studies revealed that ExT increased 
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Nrf2 and antioxidant enzymes in the RVLM, and reduced sympathoexcitation in mice 
with CHF.  
Although ExT is an effective and inexpensive way to improve the quality of life in 
CHF syndrome, low exercise capacity (exercise intolerance) is a major clinical symptom 
of this syndrome that may hinder the beneficial effects of ExT. Previous studies have 
shown that increased oxidative stress and reduced antioxidant enzymes in skeletal 
muscle causes, at least in part, skeletal myopathy, which contributes substantially to 
exercise intolerance in CHF. However, the mechanism by which antioxidant enzymes 
are declined in skeletal muscle during CHF is not known. Therefore, we hypothesized 
that Nrf2 downregulation contributes to the impaired antioxidant defense in skeletal 
muscle during CHF. We further hypothesized that activation of Nrf2, by curcumin, 
improves exercise performance in CHF. Indeed, in the CHF mouse model, Nrf2 was 
downregulated in skeletal muscle, and curcumin treatment was associated with 
improved exercise capacity and upregulated Nrf2 and antioxidant enzymes in skeletal 
muscle. Collectively, these data implicate Nrf2 as a key factor in the reduction of 
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 Cardiovascular disease (CVD) is a major health problem in the United States 
(US). Approximately 92.1 million American adults had one or more types of CVD in 
2014. It is estimated that every 40 seconds, one person in the United States dies from 
CVD. In 2014, CVD was the underlying cause of death in over 30% of mortalities and 
played a role in half of all deaths. CVD not only affects a large percentage of the 
population but also imposes a substantial burden on health care resources. The overall 
direct and indirect cost of CVD in the US in 2009 was 313 $ billion. Globally, CVD 
remain a leading cause of death, accounting for more than 17.3 million deaths 
(approximately 31% of all global deaths) in 2013 and costing $863 billion [1]. 
Because CVD is a major cause of mortality and morbidity, effective treatment is 
critical; however, the treatment effectiveness is limited because most of the current 
treatment options target symptoms in order to prevent subsequent cardiovascular events 
such as myocardial infarction and stroke. As such, the mandate for clinical and basic 
research efforts that target the primary cause is extremely important to understand the 
primary mechanisms involved in the pathogenesis of CVD. 
CVD encompasses many diseases, including CHF and hypertension, the two 
most prevalent forms of CVD. CHF is considered one of the most disabling and deadly 
diseases [2]. It is estimated that 5.8 million people are currently diagnosed with CHF, 
and each year, around 960,000 new cases are diagnosed with this disease. CHF ranks 
among the most costly chronic diseases, with an estimated cost of $30.7 billion in 2012. 
In the US, one in nine deaths certificates (300,122) listed CHF as a cause of death in 





  Heart failure (HF) is a major cause of mortality in the US and many other nations 
and characterized by a reduced ability of the heart to pump or fill with blood [1]. 
Traditionally, CHF was considered solely a hemodynamic disorder. However, because 
the therapeutic interventions that improve the hemodynamic status of CHF patients have 
no influence on cardiac performance deterioration, the hemodynamic hypothesis was not 
sufficient to explain the progression of CHF [4]. The development of the neurohumoral 
hypothesis, along with muscle hypothesis, played a role in understanding the 
progression of heart failure and demonstrated that heart failure is rather a syndrome and 
not a single disorder. Heart failure, therefore, can be defined as a syndrome that 
develops as a result of cardiac disease and characterized by symptoms and signs 
produced by circulatory, neurohumoral and skeletal muscle response to cardiac 
dysfunction [4, 5].  
Heart failure is classified as left ventricular, right ventricular, and biventricular 
depending on the location of the deficit. Depending on the duration, heart failure is 
classified as acute or chronic. Clinically, it is typically classified into two major types 
based on the functional status of the left ventricle or ejection fraction (EF): heart failure 
with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction 
(HFrEF). HFrEF is characterized by reduced LV capacity to pump blood, and hence 
oxygen (O2), proportionate with metabolic demands of the body tissues. In HFpEF, the 
EF is typically normal, but the LV wall is thickened and stiff [6]. Because the etiology, 
progression, and treatment of HFpEF remain poorly understood, the current dissertation 
focused purely on HFrEF, which will be termed as CHF for simplicity. 
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There are several etiologies (myocardial infarction, hypertension, coronary artery 
disease, cardiomyopathies, myocarditis, and valvular heart disease) that may contribute 
to the syndrome of CHF, which is characterized by adverse left ventricular remodeling 
[7]. This maladaptive left ventricular remodeling occurs due to myocyte loss and an 
increased myocardial strain, which results in left ventricular hypertrophy and fibrosis [2]. 
Thus, the myocardial O2 consumption is increased, and myocardial contractility is 
decreased, which causes a reduction in left ventricular EF [2, 8] 
Impaired myocardial contractility leads to reduced cardiac output and initiates a 
series of compensatory mechanisms to maintain arterial pressure and tissue perfusion. 
These compensatory mechanisms are collectively referred to as neurohumoral 
stimulation [9-11]. In the early phase of heart failure, these compensatory adjustments 
are beneficial and provide adequate peripheral tissue perfusion. However, these 
compensatory mechanisms become more intense over time and result in further damage 
to cardiomyocytes. The greater the damage to cardiomyocytes, the more compensatory 
actions are generated, and a vicious, positive feedback cycle develops (figure 1.1). As 
this cycle grows, cardiac reserve capacity is diminished. This reduced cardiac capacity 
becomes prominent in certain circumstances, especially during exercise which increases 
the load on the heart. This increased load rapidly utilizes the small amount of available 
reserve and cardiac output soon fails to meet the demands of the body’s level of activity. 
This decreased exercise capacity in heart failure is generally referred to as exercise 
intolerance. Decompensated heart failure usually emerges when damage exceeds the 
cardiac reserve capacity [10-12] 
There are numerous classification systems for CHF which are used for clinical 
evaluation of severity. The New York Heart Association (NYHA) classification system, 
which classifies the extent of heart failure in a simple way based on the degree of 
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exercise limitation, is widely used by clinicians [13]. This classification system ranges 
from class I (less severe/asymptomatic) to class IV (most severe; experience symptoms 
even at rest) (Table1) 
Treatment strategies are different according to each classification and range from 
physical activity and dietary changes to high dose medication including diuretics, renin-
angiotensin system (RAS) inhibitors, and in severe cases, cardiac transplantation or 
ventricular assist devices is required [2]. Some of the above treatment options target the 
compensatory component of the CHF vicious cycle and not the initiating causal factors.  
Strategies that target these primary factors are important for future therapeutics.  
 
NYHA classification system 
Class 1 No limitation of physical activity. Ordinary physical activity does not 
cause undue fatigue, palpitation, dyspnea (shortness of breath). 
Class 2 Slight limitation of physical activity. Comfortable at rest. Ordinary 
physical activity results in fatigue, palpitation, dyspnea (shortness of 
breath). 
Class 3 Marked limitation of physical activity. Comfortable at rest. Less than 
ordinary activity causes fatigue, palpitation, or dyspnea. 
Class 4 Unable to carry on any physical activity without discomfort. 
Symptoms of heart failure at rest. If any physical activity is 
undertaken, discomfort increases. 
Table 1.1 - The New York Heart Association (NYHA) classification system for extent and 






Figure 1.1 - The vicious cycle of chronic heart failure 
Schematic representation of the progression of chronic heart failure. Decreased cardiac output 
increases neurohumoral stimulation including sympathetic nervous system and renin-
angiotensin system. This increases strain on the heart leading to further decline in the function 




Neurohumoral activation in Chronic Heart Failure  
Neurohumoral activation in CHF is characterized by activation of the SNS, RAS, 
arginine-vasopressin (AVP) system and the counteracting atrial natriuretic peptide (ANP) 
and brain natriuretic (BNP) systems [10, 11]. Following a myocardial insult, volume 
overload along with impaired sodium (Na) excretion, triggers the atrial 
mechanoreceptors, which, apart from the reduction of sympathetic outflow, results in a 
vasodilatory, and natriuretic effects [14, 15]. ANP has been shown to increase in 
association with asymptomatic left ventricular dysfunction. As such, it plays an important 
role in maintaining a compensatory state in CHF [16]. The loss of these counteracting 
compensatory mechanisms may signify the beginning of symptomatic heart failure as 
the SNS becomes persistently activated. In contrast to SNS activation, which is activated 
early in the development of CHF, the RAS is usually triggered when symptoms develop. 
In addition, AVP is inappropriately released in more advanced stages when perfusion 
pressure is markedly decreased [14] 
Increased activation of the sympathetic nervous system 
Chronic activation of the SNS has been described as a part of the CHF 
syndrome [11, 17-20]. The SNS is normally modified by either inhibitory or stimulatory 
feedback mechanisms from a) aortic inhibitory mechanosensitive afferents 
(baroreceptors) and cardiopulmonary chemical and mechanosensitive afferents, b) 
excitatory afferents activated under certain conditions such as exercise (muscle 
metabolic receptors) and ischemic metabolic receptors (e.g. cardiac afferents), and c) 
central neuromodulators, which may be either excitatory such as angiotensin II (Ang II) 





The mechanism underlying persistent chronic activation of the SNS is attributed, 
in part, to abnormalities of the inhibitory afferents from cardiac chambers, aortic and 
carotid arteries. These abnormalities lead to the withdrawal of a sympatho-inhibitory tone 
on the vasomotor center in the medulla [11]. In the CHF dog model (chronic 
tachycardia), atrial baroreceptor sensitivity is decreased [22, 23], which may contribute, 
via increased AVP release, to some of the clinical characteristics of CHF such as 
edema, ascites, hyponatremia and renal vasoconstriction [24]. In addition, volume 
expansion, which stimulates low-pressure baroreceptors throughout the 
cardiopulmonary tree, results in a blunted suppression of renal sympathetic nerve 
activity in dogs with CHF [25]. The primary modulator of short term sympathetic 
vasomotor tone (arterial pressure) is the arterial baroreflex (ABR) [26]. ABR sensitivity is 
depressed in some forms of hypertension as well as in CHF patients and animals [27-
29]. The underlying mechanism for blunted baroreflex sensitivity involves decreased 
discharge sensitivity of the carotid sinus nerve, which is mediated in part by an increase 
in Na+-K+ ATPase activity [30, 31]. Central neural components that mediate the ABR 
are also involved in blunted baroreflex sensitivity. For instance, in dogs with CHF, 
bypassing the receptor ending by stimulating an isolated carotid sinus nerve, resulted in 
an impaired baroreflex response [31]. While an impaired baroreflex control of 
sympathetic nerve activity is initiated in the early stages of left ventricular dysfunction, 
plasma NE was not attenuated after cardiac denervation suggesting that ABR 
depression is not necessary for chronic elevation of SNS activity [32, 33]. Growing 
evidence suggests that other mechanisms may substantially contribute to persistent 
activation of SNS activity. These mechanisms include the skeletal muscle ergoreflex and 
the arterial chemoreflex [11]. 
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Carotid body chemoreflex 
Enhanced activation of the carotid body chemoreflex has been shown in humans 
and animals with CHF. The underlying mechanism is related to an increased level of 
Ang II and decreased NO• in the carotid body [34, 35]. These alterations inhibit voltage-
gated K+ current, which results in an enhanced carotid body sensitization to hypoxia as 
well as elevated resting afferent chemoreceptor activity under normoxic conditions [36]. 
Furthermore, chronic reduction of blood flow and reduced shear stress in the carotid 
body reduces Krüppel‐like Factor 2 (KLF2) expression, a shear stress-sensitive 
transcription factor that targets genes associated with antioxidant defense and nitric 
oxide synthase (eNOS). [37, 38]. This finding is further supported by evidence that the 
degree of augmented carotid body chemoreflex is correlated with the degree of LV 
dysfunction [39].  
Cardiac sympathetic afferent reflex  
Discharge from excitatory cardiac sympathetic afferent nerves is enhanced in 
CHF animals [40, 41]. These ischemia sensitive neuronal endings reside mainly in the 
epicardial region of the left ventricle. Under normal conditions, these neuronal afferents 
have little impact on SNA, however, in CHF these afferent endings become sensitized 
and are activated by several chemical mediators released from the ischemic 
myocardium [42]. Epicardial application of bradykinin and hydrogen peroxide, as well as 
volume expansion, produced an enhanced cardiac sympathetic afferent reflex, indicating 
that cardiac sympathetic afferent endings are sensitized in CHF [43, 44]. Furthermore, 
the central gain of cardiac sympathetic afferents is enhanced in CHF [40, 41]. This 
enhanced gain is mediated by the central increase in Ang II and reduced NO• at the 
levels of the NTS, PVN and RVLM [45-47]. In addition, afferent input from cardiac 
sympathetic afferents impact the integration of peripheral reflex input at the level of the 
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NTS via an Ang II mechanism. Cardiac sympathetic afferents potentiate the peripheral 
carotid body chemoreflex activation of sympathetic outflow and contribute to the 
impaired baroreflex inhibition of sympathetic outflow in CHF [48, 49]. 
Exercise pressor reflex  
The exercise pressor reflex (ergoreflex) originates from the stimulation of 
group III (mechanically sensitive) and group IV (metabolically sensitive) sensory endings 
in contracting skeletal muscle. During exercise, ergoreceptor afferent signals travel in 
the lateral spinothalamic tract and mediate sympathetic vasoconstriction as well as an 
increase in ventilation [50]. While there is a substantial agreement that the ergoreflex is 
exaggerated in CHF [50-52], the role of mechanical and metabolic components of the 
ergoreflex remains controversial. Human and animal studies suggest that the 
mechanical component is sensitized, whereas the metabolic component is blunted in 
CHF [53, 54]. Other studies have shown that the metabolic component is enhanced [54, 
55]. This controversy in the role the metabolic receptors may be related to the type of 
muscle work being done as some studies have utilized static muscle contraction, 
whereas others utilized rhythmic exercise to activate sensory afferents endings. For both 
rhythmic and static handgrip exercise, a dynamometer was used to measure force 
production. The basic difference between the two forms of handgrip exercise is that in 
static handgrip exercise, the contraction is isometric, for example, gripping the 
dynamometer at 60% of maximal voluntary contraction for a certain period of time, 




Abnormalities in central nervous system control of the sympathetic outflow  
Studies performed on pacing-induced CHF dogs demonstrate that baroreflex 
denervation [57] and ß-adrenergic blockade [33] have no influence on neuro-humoral 
drive suggesting that central mechanisms may contribute to elevated neuro-humoral 
stimulation. The forebrain, hypothalamus, and brainstem are the major areas that 
contain core neuronal circuits which initiate and adjust reflexes to maintain homeostasis. 
Figure 1.2 shows the central neuronal pathways that regulate cardiovascular function. 
These central neuronal networks are updated continuously on the status of 
cardiovascular, respiratory, gastrointestinal, and other vital organs via visceral afferents 
that project to the NTS [58]. Circulating hormones and blood born factors sensed by 
circumventricular organs such as the subfornical organ (SFO) also contribute to the 
regulation of central neuronal networks [59]. A prominent reflex incorporated by these 
central autonomic networks is the baroreflex arc in which afferent fibers from high-
pressure baroreceptors project to the NTS. An increase in arterial pressure stimulates 
baroreceptor firing which evokes NTS excitatory projections (glutamatergic) to the 
caudal rostroventrolateral medulla (CVLM), which sends inhibitory projections 
(GABAergic) to the RVLM [60]. The RVLM has a direct projection to the intermediolateral 
(IML) cell column of the spinal cord where it synapses with sympathetic preganglionic 
neurons and ultimately end-organ sympathetic nerves. In addition, excitatory inter-
neurons project from NTS to cardio-inhibitory areas (nucleus ambiguous and dorsal 
motor nucleus of vagus), which account for the primary cardiac component of the 
baroreflex. As mentioned above circumventricular organs such as the SFO and the 
median preoptic nucleus, which contain osmosensitive neurons can sense circulating 
factors. These centers send projections to hypothalamic nuclei such as the 
paraventricular nucleus (PVN), which has a direct projection to sympathetic 
preganglionic neurons and to the RVLM. For instance, atrial volume receptors project to 
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the NTS, which suppresses PVN activity through GABAergic interneurons resulting in 
decreased sympathetic nerve activity to the kidney. The PVN, therefore, plays a key role 
in mediating the reduction of sympathetic nerve activity in response to volume expansion 
[61]. It is well-established that the PVN is a key mechanism for blood volume regulation. 
Atrial mechanoreceptors sense blood volume changes. The signals from these receptors 
are conveyed to the NTS by vagal afferents. An increase in the blood volume triggers a 
reflex decrease in renal sympathetic nerve activity, which results in renal vasodilation 
and increased urine flow and sodium loss [62]. 
Abnormalities of central neuronal regulation are potential mechanisms for 
enhanced central sympathetic outflow in CHF. Major mechanisms for centrally mediated 
enhanced sympathetic outflow involve activation of Ang II, angiotensin receptors and an 
increased level of reactive oxygen species (ROS) [63, 64]. Other mechanisms also 
involved in enhanced central sympathetic outflow such blunted NO•. inhibition of 
sympathetic outflow [18], inflammatory cytokines, and activation of excitatory 
neurotransmitters [65]. However, a comprehensive discussion of these factors are out of 
the scope of this dissertation.  
Renin-Angiotensin System 
 It has long been  known that the RAS plays a key role in the progression of CHF 
[66] [17] [67]. The RAS is an endocrine system, which plays an important role in 
regulating extracellular fluid and electrolyte balance thereby maintaining cardiovascular 
homeostasis [12]. The key determinant of RAS activity is renin secretion by 
juxtaglomerular cells in the kidney. Renin secretion is stimulated by Low renal perfusion, 
decreased NaCl flux sensed by macula densa and sympathetic β1-adrenergic 
stimulation of juxtaglomerular cells [68]. Renin regulates the rate-limiting step of RAS by 
cleaving angiotensinogen, which is constitutively secreted by the liver, to form 
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biologically inert angiotensin-I. Angiotensin-I is then cleaved by the membrane-bound 
angiotensin-converting enzyme (ACE) to form biologically active Ang II, which is 
considered the primary effector peptide of the RAS system [69]. In addition, angiotensin-
I can be cleaved by angiotensin-converting enzyme 2 (ACE2) to form Ang-(1-7) and  
Ang-(1-9). Ang-(1-9) can be further cleaved by ACE to form Ang-(1-7). Ang II mediates 
its cellular effects by binding to G-protein coupled, angiotensin type 1 receptor (AT1R) 
and angiotensin type 2 receptor (AT2R). The Ang II-AT1R signaling pathway is complex 
and involves phospholipid (phospholipase C), alterations of gene transcription factors (c-
fos and c-jun), activation of tyrosine kinases, and activation of membrane-bound ROS 
generating enzymes such as nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidases [70-72]. AT2R and the mas receptor are involved in counteracting the AT1R 
actions and thus comprise the protective arm of RAS signaling [73-75]. Indeed, previous 
studies from our lab and others have demonstrated the potential therapeutic effect of 
ACE2-MasR on cardiovascular diseases such as CHF [76] and hypertension [77]. 
Pharmacological inhibitors of RAS, such as captopril (ACE inhibitor) and losartan (AT1R 
blocker) are widely used in treating CHF and hypertension [78] [79]. 
Previously, it has been thought that high levels of circulating Ang II in CVD such 
as CHF and hypertension do not pass the blood-brain barrier, as this peptide is too large 
to have access to the central cardiovascular control areas. However, Biancardi et al. [80] 
observed that fluorescent-labeled Ang II can extravasate into the cardiovascular control 
areas in the hypothalamus and brain stem along with increased blood-brain barrier 
permeability indicating that peripheral Ang II has direct access into central areas of 
cardiovascular control. In addition, circumventricular organs in the brain such as the 
SFO which lack a blood-brain barrier have an important role in Ang II regulation of blood 
pressure due to their ability to sense and detect circulating factors [81, 82].  
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It also appears that the area postrema plays a role in chronic hypertension. 
Chronic intravenous Ang II infusion (5-10 days) results in a transient increase in the 
mean arterial pressure in area postrema ablated rats, whereas in controlled sham-lesion 
rats, chronic Ang II infusion results in sustained hypertension [83]. 
In addition to the effects of circulating Ang II on central neuronal activity, the 
brain contains its own RAS. Ganten et al. [84] demonstrated that Ang II is detected in the 
brain of nephrectomized dogs, suggesting that the brain RAS is altered independently of 
the peripheral RAS. The RAS is also found intracellularly within neurons [85]. This 
suggests that the RAS, particularly Ang II acting as a neurotransmitter or 
neuromodulator alters neuronal activity, thus affecting sympathetic outflow. In cultured 
neurons, AT1R stimulation increases Ca+2 current, while inhibiting both the delayed 
rectifier K+ current (IKv) and transient (A‐type) K+ current (IA) and these alterations in ionic 
currents were associated with an enhanced neuronal firing [86].  
 The link between Ang II intraneuronal signaling and increased sympathetic 
nervous activity in the setting of CHF has been supported by numerous studies. It is well 
accepted that Ang II-induced sympathoexcitation in the setting of CHF is mediated, at 
least in part, by reactive oxygen species (ROS) through the AT1R [87-89] 
Arginine vasopressin  
Circulating plasma levels of AVP is increased in humans with CHF [90, 91] and 
animal models of CHF [92, 93]. The precise mechanisms for AVP release from the 
posterior pituitary involve factors other than plasma osmolality. For instance, in CHF 
patients, reducing plasma osmolality did not reduce AVP concentration [94]. These 
factors are related to a decrease in atrioventricular compliance and therefore decreased 
in stretch receptor sensitivity that leads to the impairment in baroreceptor-mediated 
inhibition of AVP release [94]. Another factor is Ang II which directly stimulates AVP 
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release from the posterior pituitary [95]. Plasma levels of AVP are increased in parallel to 
an increase in plasma renin activity, possibly due to compromised organ perfusion [91] 
Atrial natriuretic peptide 
ANP is synthesized in the atria and released in response to atrial stretch. ANP 
exhibits a vasodilatory effect via inhibition of NE release. It also exerts a direct 
vasodilatory effect as well as a natriuretic effect [11]. ANP is released in the early 
asymptomatic stages of CHF in response to increased cardiac filling pressure, thus acts 
as a compensatory mechanism to reduce cardiac volume overload. Persistent atrial 
stretch, however, impairs atrial compliance and decreases ANP levels, which results in 
blunted ANP release in response to atrial stretch [91]. Ventricular brain natriuretic 
peptide (BNP) has a similar function to ANP and is released from the ventricular 
myocardium in response to ventricular stretch and causes vasodilation and natriuresis 
[96]. The rise in BNP seems to be a more accurate measurement compared to ANP in 
the detection of left ventricular systolic dysfunction [97], and it is considered an 







Figure 1.2 - Schematic of cardiovascular control centers in the mouse brain 
In the normal condition, CVLM provides a tonic inhibitory control of RVLM neurons which reduces the vasomotor 
tone. In the setting of CHF, impaired baroreflex function leads to decreases NTS afferent activity, this results in 
removal of the tonic suppression of the RVLM activity from the CVLM and results in increased sympathetic 
outflow to end organs. Additionally, central angiotensin signaling, especially in circumventricular organs, increased 




 Rostro-ventrolateral medulla (RVLM) 
As mentioned above, increased arterial pressure results in inhibition of vasomotor 
medullary area, which contains spinally projecting pre-sympathetic neurons. This group 
of pre-sympathetic neurons collectively referred to as RVLM [60]. RVLM neurons are 
responsible for the tonic sympatho-excitatory drive for vasomotor tone and considered a 
key site for the integration of multiple reflexes that mediate changes in sympathetic 
nerve activity and blood pressure [26]. A unique property pf the RVLM is that, unlike 
other presympathetic nuclei, it does not send projections to parasympathetic 
preganglionic neurons [60], suggesting that the RVLM plays an important role in 
controlling sympathetic vasomotor tone. 
In anesthetized rats, RVLM excitation markedly increases arterial pressure and 
heart rate. Conversely, acute inhibition of the RVLM reduces these parameters to the 
same extent as cervical spinal cord dissection [99], this suggests that the basal 
vasomotor drive is primarily mediated by the RVLM. Neurons within the RVLM, most 
probably the adrenaline synthesizing neurons (C1), are key neurons that influence 
sympathetic vasomotor fibers and HR. These neurons have a discharge pattern that is 
similar to barosensitive sympathetic efferent and considered an integral part of the 
baroreceptor reflex arc [100].  
Approximately 50 -70% of pre-sympathetic RVLM neurons are C1 neurons, 80% 
of which synthesis glutamate [60]. Intrathecal administration of Kynurenate, a glutamate 
receptors antagonist, in the thoracic spinal cord dramatically reduced sympatho-
excitatory response produced by RVLM stimulation [101], suggesting that bulbospinal 
RVLM neurons use glutamate as a neurotransmitter to excite sympathetic preganglionic 
neurons. In addition, 60 to 70% of presympathetic neurons are catecholaminergic 
neurons [102], however, 80% of catecholaminergic neurons contain vesicular glutamate 
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mRNA[103]. It has been suggested that the bulbospinal catecholaminergic neurons exert 
modulatory effects on the activity of sympathetic preganglionic neurons. Experiments on 
rats using intrathecal administration of noradrenaline or adrenaline reveal that 
catecholamines may stimulate (probably via alpha 1 adrenoreceptors) or inhibit (alpha 2 
adrenoreceptor) preganglionic sympathetic neurons [104].  
The mechanism by which RVLM neurons generate sympathetic vasomotor tone 
is not clear. Historically, two views have been proposed; RVLM neurons have the 
capability to display pacemaker-like activity and therefore can generate action potentials 
without synaptic input. In contrast, others have suggested that the RVLM requires 
synaptic input to generate tonic activity [60]. Angiotensin II and reactive oxygen species 
play an important role in regulating the tonic activation of RVLM neurons [63]. Other 
substances such as glutamate, catecholamines, acetylcholine, NO. and Substance P 
also affect RVLM neuronal activity but are beyond the scope of this dissertation.  
Reactive oxygen species (ROS) in the central nervous system  
Over the past decade, one of the most prominent notions that have emerged in 
the field of cardiovascular research is that ROS act as intracellular signaling 
molecules[105]. ROS are simply defined as highly reactive biomolecules that contain O2 
[106]. Unlike free radicals, ROS do not always have an unpaired electron, thus, not all 
ROS are free radicals. Following a one, two, or three O2 reduction, superoxide (O2.-), 
hydrogen peroxide (H2O2), and hydroxyl radicals (HO.) are produced. ROS are produced 
by enzymatic reactions, as with production of O2.- by NADPH oxidase (NOX) and 
xanthine oxidase, interaction with each other as with production of peroxynitrite (ONOO-) 
from the reaction of nitric oxide (NO.) with O2.-, interaction of ROS with metals, as in HO. 
production from the reaction of H2O2 with Fe+2, or by mitochondrial electron transport 
chain. [107, 108]. The role of ROS in the phagocytotic process was one of the first 
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observations for a physiological role of ROS when it was discovered that ROS are 
necessary for the destruction of pathogens. [109] [110]. In fact, if ROS production is 
disturbed, patients suffer from a disease known as a chronic granulomatous disease 
[111].  
  Accumulating evidence demonstrates that ROS are not only essential 
participants in cell signaling but also play a role in cellular damage and contribute to the 
pathogenesis of a number of human diseases [105]. This paradox in the role of ROS as 
biomolecules participating in the regulation of cellular function and as cellular toxic by-
products is perhaps related to differences in the concentration of ROS produced. 
Excessive production of cellular ROS causes DNA mutation, lipid peroxidation, structural 
and functional alterations of proteins and consequently cellular death [112]. As such, 
cells have a complex system for protecting against changes in the redox environment. 
This system includes a number of antioxidant enzymes such as superoxide dismutase 
(SOD), catalase, and glutathione peroxidase. These antioxidant enzymes are distributed 
within certain subcellular compartments. For example, SODs are located in either the 
cytoplasm (SOD1, CuZnSOD), extracellular space (ecSOD, SOD3) or mitochondria 
(SOD2, MnSOD). Catalase and glutathione peroxidase are residing in peroxisomes and 
cytoplasm, respectively [58]. When ROS are excessively produced due to disruption 
antioxidant enzyme production, overactivation of ROS-generating enzymes, or 
mitochondrial abnormalities, a deleterious condition called “oxidative stress” occurs [58]. 
It is well established that oxidative stress is involved in many pathological conditions 
such as CHF and hypertension [113-115]. 
Harrison and Griendling [116] were the first to demonstrate the relationship 
between Ang II and ROS generation in the cardiovascular system in normal and disease 
states. Ang II-mediated superoxide (O2•–), generated through NOX enzymes, leads to 
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endothelial dysfunction and the pathogenesis of hypertension [116-118]. Because of 
accumulating evidence suggesting that ROS mediate a variety of acute and chronic 
effects in the cardiovascular system, their role in altering autonomic outflow in disease 
conditions has become of interest. Several studies have now shown that ROS stimulates 
sympathetic outflow [119, 120]. More importantly, the link between Ang II simulation and 
ROS has been supported by numerous studies. In the central nervous system, Ang II 
produces ROS from two main sources; NOX enzymes and the mitochondrial electron 
transport chain [121]. Ang II induces enzymatic activity and expression of NOX that lead 
to enhances O2 reduction to O2•– via the transfer of a single electron from NAD(P)H [58]. 
Ang II also reduces the activities of complexes I and III of the mitochondrial electron 
transport chain, which interfere with electron transport between complexes resulting in 
electron leakage and increased generation of  O2•–  [122]. In addition to NAD(P)H 
oxidase and mitochondrial mechanisms in ROS production, an interplay between 
NAD(P)H-derived O2•–  and the mitochondrial electron transport chain represent another 
mechanism of oxidative stress via a ROS- induced ROS mechanism. For instance, in the 
RVLM of Wistar Kyoto Rat (WKY) rats, Ang II-mediated increase in oxidative stress 
reduced enzymatic activity of the electron transport chain and was associated with 
increased mitochondrial hydrogen peroxide (H2O2). Microinjection of the p22phox subunit 
antisense into the RVLM prevented the increase in mitochondrial H2O2 after Ang II 
treatment, suggesting that NAD(P)H-derived O2•–  induces a feedforward dysfunction of 
the electron transport chain [122].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
 The NOX are a family of enzymes consisting of multiple isoforms (Nox1-5, and 
DUOX1-2) that are expressed in varied tissues and subcellular specific locations for 
each enzyme [123]. Of all Nox enzymes, two that are closely implicated in the 
pathogenesis of CVD and have been found to mediate the pressor effect of Ang II are 
Nox 2 and Nox 4. While both enzymes are required for the Ang II pressor effect when 
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injected into the SFO, only Nox2 was found to be associated with the Ang II-induced 
drinking response [124]. The differential role of both Nox’s may be partially attributed to 
different subcellular localizations within neurons, as Nox4 is localized to neuron 
mitochondrial [125], while Nox2 primarily resides in the plasma membrane[123]. 
Accumulating evidence indicates that in central neurons that have major control over 
cardiovascular function such as the PVN and RVLM, Ang II, binds to AT1R, which 
activates Nox2, leading to O2•– production within these neurons which results in 
stimulation of sympathetic nervous activity [126-128]. Removal of O2•– by selective 
overexpression of CuZnSOD in the mice SFO, a brain area known to be a primary 
sensor for blood born Ang II, prevented hypertension and the associated increase in O2•–  
indicating that the O2•–  is required for the central response to Ang II [129].  
 In humans, evidence has begun to emerge that suggest a role for ROS in the neuro-
humoral activation associated with CHF. A clinical study [130], has shown that acute 
antioxidant treatment with vitamin C improves baroreflex function, most likely by 
improving endothelial dysfunction and promoting vasodilation. Furthermore, multiple 
evidence suggest that antioxidant therapy delivered to the carotid sinus [131] as well as 
in central autonomic nuclei such as the RVLM [132, 133] improves baroreflex sensitivity 
in animals with CHF, indicating that antioxidants contribute to neuronal control of 
baroreflex function. SOD protein microinjection into the RVLM of anesthetized swine 
produced a reduction in renal sympathetic nerve activity. This evidence supports the 
involvement of ROS in the regulation of sympathetic nerve activity [134]. Our lab has 
shown a relationship between Ang II and ROS as contributors to sympathoexcitation in 
CHF. In a rabbit model of pacing-induced CHF, intracerebroventricular administration of 
Ang II increased renal sympathetic nerve activity which was associated with an 
upregulation of Nox2 and increased Nox2-dependent superoxide anion in the 
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RVLM.[113] These responses were abolished by the administration of the SOD mimetic 
tempol or the Nox2 inhibitor, apocynin. Furthermore, the expression of both CuZn SOD 
and MnSOD was downregulated in the RVLM of rabbits with CHF and overexpression of 
CuZn SOD into the RVLM decreased baseline sympathetic nerve activity [113, 133]. 
These findings suggest that in the RVLM of rabbits with CHF, pro-oxidant mechanisms 
contribute to sympatho-excitation and that the enhancement of antioxidant pathways 
may contribute to the normalization of sympathetic nerve activity in CHF.    
A major mechanism by which ROS mediates an increase in sympathetic outflow 
by central neurons in CHF is a redox modulation of ion channels such as Ca+2 and K+ 
channels that play an important role in the generation of action potentials and neuronal 
excitability and have been shown to be regulated by ROS [135]. Evidence from both in 
vivo and in vitro studies has shown that ROS, especially O2•–,  derived from Nox2 and 
mitochondria are involved in Ang II-mediated modulation of Ca+2 and K+ channels [136-
138]. While O2•–  acts as an intermediate for Ang II-induced neuronal ion channel 
modulation, as discussed above, NO• mediates Ang-(1-7)-induced increase in neuronal 
K+ current [139], thus acting as a sympatho-inhibitory molecule in the central neurons. 
Because of the opposite effects of O2•–  and NO• on neuronal ion channels, it is plausible 
that the balance between these 2 radicals is crucial in maintaining sympathetic outflow 
given the fact the reaction between  O2•–  and NO• is diffusion-limited. As such, the 
downregulation of NO• in the central neurons such as in the PVN and RVLM  [140, 141], 
is partially caused by increased O2•– .  Another mechanism by which ROS increases 
sympathetic outflow in CHF involves astrocytes and glutamate signaling. Ang II has 
been shown to inhibit astrocyte glutamate transporter function, leading to increased 
extrasynaptic glutamate and thus excitation of presympathetic neurons [142]. Given the 
fact that ROS impairs glutamate transporters in cortical astrocytes leading to 
23 
 
neurotoxicity [143], it is possible to speculate that Ang II induces ROS production in 
central brain areas that contribute to inhibition of glutamate transporter function.    
The intracellular signaling pathway through which ROS mediate an increase in 
sympathetic outflow involves a number of redox-sensitive proteins. Some of the 
upstream mediators include protein kinase C (PKC) and redox-sensitive Calcium 
Calmodulin-dependent protein kinase (CaMK) proteins. Furthermore, inhibition of these 
two proteins in primary neurons cultured from rat hypothalamus abolished the Ang II-
mediated reduction in K+ current [137]. NOX 2 represents a critical link between Ang II-
mediated production of these two proteins and ROS generation. One of the important 
downstream mediators of ROS signaling is mitogen-activated protein kinase (MAPK). In 
the RVLM, Ang II-mediated activation of PKC-NOX-ROS signaling cascade has been 
shown to trigger activation of p38MAPK, which in turn, mediates a short-term pressor 
response of Ang II via enhancement of glutamate release to RVLM neurons [144]. In 
addition, ROS-mediated activation of extracellular signal-regulated protein kinase 
(ERK)1/2 has been shown to mediate the long-term pressor response of Ang II. For 
instance, in rabbit RVLM, the Ang II-AT1R-mediated activation of PKC lead to NADPH-







Exercise training  
It has been generally well accepted that habitual physical activity is inversely 
associated with all-cause mortality and CVD mortality. Initial observations of Morris. et 
al., in 1953 [146] , illustrated that workers who are physically active had a lower coronary 
heart disease mortality rate compared with their sedentary co-worker counterparts. 
Multiple observational and epidemiological studies have been conducted, yielding similar 
results; physically active individuals have lower rates of coronary heart disease and CVD 
than inactive individuals [147-149]. Based on these studies, and subsequent multiple 
lines of evidence, the American Heart Association in 1992, recognized physical inactivity 
as an independent risk factor for CVD [150]. While the inverse association of physical 
activity and CVD is mainly derived from observational studies, and therefore, cannot 
prove a cause and effect relation, multiple randomized controlled trials support a causal 
relation [148, 151]. Given the relationship between SNS overactivity and CVD mortality, 
it becomes apparent that physical activity-induced alteration of SNS in otherwise healthy 
individuals is important in reducing CVD incidence. More importantly, it has been 
suggested that physical activity has multiple beneficial effects on the cardiovascular 
system in disease states. These effects include reduction of blood pressure and 
sympathetic outflow in humans [152-154], and animals [155, 156]. CVD such as 
hypertension and CHF are associated with overactivity of the sympathetic nervous 
system [9, 58]. Because morbidity and mortality in hypertension and CHF are often 
associated with elevation of SNS activity, it is likely that the beneficial effects of physical 
activity are related, at least in part, to the reduction of SNS activation.  
Prior to 1990, ExT was thought to be detrimental to patients with CHF, regardless 
of severity. In fact, exercise was thought to further worsen left ventricular function [157]. 
While this is still true for patients with severe CHF, there is a spectrum of CHF patients 
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who are ambulatory and able to perform ExT. For these patients, ExT tends to be 
beneficial, not only in terms of quality of life, but there are now data that suggest it 
prolongs life [158-160]. Coats et al. [161] performed the first randomized controlled trial 
of ExT in patients with stable CHF in 1990, demonstrating that 8 weeks of ExT increased 
VO2 max by 18%. After this groundbreaking finding, attention was gradually drawn to the 
beneficial effects of ExT in CHF patients. During the period from1999 to 2010, multiple 
randomized control trials [160, 162-165] and metanalyses [165, 166] [166, 167] 
suggested that ExT has beneficial effects on quality life, functional capacity, 
hospitalization and mortality. The largest-scale prospective study to date is the 
Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION). In this 
randomized, multicenter controlled trial, 2331 patients with stable CHF (EF≤34%), were 
randomly assigned to usual care plus aerobic ExT or to usual care alone. The results of 
HF-ACTION clearly indicated that an ExT program over 2.5 years significantly improved 
quality of life. While all-cause mortality and hospitalization were not altered by ExT, there 
was a borderline significant reduction in cardiovascular mortality and CHF 
hospitalization. After adjustment for 4 confounding factors, ExT was associated with a 
significant reduction of all-cause mortality and hospitalization [168-170]. Collectively, 
these studies indicate that ExT is a safe and effective nonpharmacological strategy for 
treatment of CHF. While there is an agreement that ExT is beneficial for CHF patients, 
the underlying mechanisms for these effects are not fully clear.  
Exercise intolerance 
Given that LV function is impaired in CHF, it was historically presumed that LV 
dysfunction is related to the degree of exercise intolerance. As such, the prevailing 
hypothesis in the past was that hemodynamic factors in CHF mediate exercise 
intolerance. Furthermore, the limits of physical activity occur at the maximal oxygen 
26 
 
uptake (VO2 max) which, by definition, equals the product of heart rate, stroke volume, 
and arteriovenous oxygen difference (Fick principle) [171]. Therefore, it was presumed 
that reduced peripheral blood flow would result in under perfusion of exercising skeletal 
muscle and consequent early onset of intramuscular acidosis, which triggers the 
ergoreflex and hyperventilation [172]. However, several interventional studies 
demonstrated that even after pharmacological improvement of blood flow and O2 
delivery, exercise capacity in CHF patients did not improve [173-175]. In addition, 
correlational studies failed to show a significant relationship between exercise capacity 
and cardiac function [176, 177]. These findings, therefore, suggest that the impaired 
cardiac function at rest is not a primary cause of reduced exercise capacity in CHF 
patients. 
After the advent of the muscle hypothesis promoted by Coats [52], attention has 
been drawn toward the peripheral consequences of CHF. Peripheral vasoconstriction is 
initially an important adaptation in heart failure, and it serves to maintain perfusion of 
vital organs such as the brain [178]. However, persistent, long term vasoconstriction 
becomes exaggerated and results in several adverse adaptations in peripheral tissues 
such as skeletal muscle [179]. The underlying mechanism for CHF-induced 
vasoconstriction involves overactivation of endocrine and nervous systems (i.e. RAS and 
sympathetic nervous system). Furthermore, during exercise, sympathetic overactivation 
is further increased due to altered sensitization of nerve endings (group III and IV 
afferents) within skeletal muscle [180, 181]. Also, vascular resistance in skeletal muscle 
fails to decrease during exercise in CHF patients, and flow to non-exercising tissues is 
maintained at the expense of exercising muscle (impaired normal distribution of cardiac 
output during exercise) [182, 183]. This occurs in a way that is independent of reduced 
cardiac output and is related, in part, to the reduction in the bioavailability of biochemical 
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mediators such as NO• that oppose local vasoconstriction [184, 185]. Collectively, these 
effects result in impaired blood flow and its proper redistribution toward skeletal muscle 
during exercise. The consequence of these effects is that during exercise, skeletal 
muscle O2 demands are not met, which leads to a greater reliance on anaerobic 
metabolism and early onset of myofibrillar acidosis [186]. This and other anaerobic 
byproducts, such as lactic acid, potassium (K+), adenosine, and bradykinin trigger the 
ergoreflex, which stimulate ventilation and increases the work of breathing [187]. This 
reduces skeletal muscle blood flow even further as hyperactivated breathing muscles 
compete with locomotor muscles for blood and O2 [188]. The under perfusion as a result 
of sympathetic overactivation not only impairs oxidative metabolism, but also provokes 
oxidative stress and inflammation, which are associated with skeletal muscle wasting, 
alteration in excitation-contraction coupling, and abnormal metabolism [172, 189-192]. 
These features together are collectively referred to as skeletal myopathy.  
Skeletal myopathy 
  The salient features of skeletal myopathy in CHF include muscle fiber atrophy, a 
shift in muscle fiber type from slow, oxidative to fast glycolytic types, decreased capillary 
number per muscle fiber, a rapid increase in muscle acidosis, and decreased 
mitochondrial density and oxidative enzyme content [190]. These features of skeletal 
myopathy correlate not only with the severity of CHF [190, 193] but also with the degree 
of exercise impairment [194-196]. SNS overactivation in CHF is a major contributor to 
skeletal myopathy via mechanisms such as tissue hypoxia, oxidative stress, 
inflammation, altered skeletal muscle metabolism, and excitation contraction 
abnormalities [190]. Sympathetic hyperactivity-induced vasoconstriction leads to skeletal 
muscle hypoperfusion and ischemia, followed by ROS release, which triggers muscle 
inflammation in part via nuclear factor kappa-light-chain-enhancer of activated B cells 
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(NF-κB) signaling pathway  [197]. Proinflammatory cytokines such as tumor necrosis 
factor-alpha (TNFα) has been shown to induce skeletal muscle atrophy in CHF via 
apoptosis [198]. Also, increased SNA leads to abnormal metabolism. For instance, the 
infusion of epinephrine into skeletal muscle during isotonic tetanic contraction increases 
the production of lactic acid in healthy humans and animals [199, 200]. In CHF, NE 
release during exercise is accentuated, and lead to the production of lactic acid at a 
lower workload [201]. Furthermore, increased ROS levels disrupt excitation-contraction 
coupling by oxidizing the contractile machinery such as SERCA, which impairs Ca+2 
sequestration after Its release from the sarcoplasmic reticulum [202].  
Oxidative stress in CHF-induced skeletal myopathy 
 Both ROS production and content are enhanced in skeletal muscle of animals 
with CHF [203, 204]. There are numerous sources of ROS generation in skeletal muscle. 
These sources include mitochondrial, which is a predominant source of ROS in skeletal 
muscle, Nox2, NO•, and xanthine oxidase [205]. Enhanced ROS production in skeletal 
muscle substantially contributes to the CHF skeletal myopathy by altering both structural 
and functional quality of muscle proteins [206]. A major characteristic of skeletal 
myopathy in CHF is atrophy, which is partially mediated by oxidative stress, resulting in 
a reduction of myofibrillar protein synthesis and/ or increased protein degradation [207]. 
For instance, oxidative stress interferes with PI3K/AkT/mTOR signaling, which is a major 
pathway involved in myofibrillar synthesis. Also, oxidative stress impairs the mammalian 
target of rapamycin (mTOR) assembly, and therefore, prevents phosphorylation of 
downstream proteins involved in myofibrillar protein synthesis [208]. Furthermore, 
oxidative DNA damage activates tumor protein 53 (P53) which has been shown to inhibit 
mTOR [209]. Concerning proteolysis, growing evidence demonstrates that oxidative 
stress promotes skeletal muscle protein breakdown through activation of the ubiquitin 
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proteasome system (UPS). For instance, exposure of myotubes C2C12 to H2O2 
upregulated the expression of ubiquitin ligase (E3) enzymes atrogen-1and muscle-
specific RING finger protein 1(MuRF1) enzymes [210]. Atrogen-1 not only promotes 
degradation of MyoD, a master regulator of skeletal myogenesis, but also involved in 
sarcomeric protein degradation [211]. MuRF1 ubiquitinates multiple structural proteins of 
skeletal muscle such as actin [212] myosin heavy chains [213] and myosin light chains 
[214]. Furthermore, by oxidizing skeletal muscle proteins, ROS enhances its 
susceptibility to protease-mediated degradation. By using purified protease, Davies et al. 
were the first to demonstrate that the oxidative modification of bovine serum albumin 
(BSA) protein enhances its susceptibly to proteolytic degradation [215]. This finding has 
been expanded by others, it is now well established that oxidative stress-mediated 
oxidized myofibrillar proteins are promptly degraded by several proteases including the 
20S proteasome and caspase 3 [216, 217].  
In addition to atrophy, the decreased strength in CHF-induced skeletal myopathy is 
caused by alterations in the contractile proteins. Reid et al. [218] were the first to 
demonstrate a relationship between redox balance and muscle force production. They 
developed a theoretical model which predicts that a deviation from the optimal redox 
state leads to a loss of muscle force production. In agreement with this model, 
subsequent studies have shown that a low basal level of ROS in skeletal muscle is 
essential for normal force production[219]. Furthermore, a modest increase in skeletal 
muscle ROS increases force production [218]. However, this positive impact of ROS on 
muscle force production is reversed when ROS concentration becomes very high [218]. 
Proteins involved in excitation-contraction coupling, such as sarcoplasmic endoplasmic 
reticulum 2 (SERCA2), and ryanodine receptor 1 (RyR1), are redox-sensitive targets in 
skeletal muscle [218]. As such, oxidative stress in skeletal muscle in the CHF state may 
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lead to Ca+2 cycling abnormalities and therefore, reduced skeletal muscle force 
production and muscle fatigue [220]. Furthermore, oxidative stress reduces myofibrillar 
Ca+2 sensitivity [221] and impairs contractile function. For instance, in soleus muscle of 
rats with CHF, the velocity of actin filament shortening was negatively correlated with 
oxidized myosin heavy chain, indicating that oxidative stress may contribute to 
depresses skeletal muscle performance [222]. We understand that oxidative stress also 
impairs cardiac function, but since the focus of this dissertation is on Nrf2 in the brain 
and skeletal muscle, we will not discuss oxidative stress in the heart.  
Nrf2/Keap-1 signaling pathway 
Initial observations in 1986 in the cancer chemoprevention field demonstrated 
that 2 (3)-tert-butyl-4-hydroxyanisole (BHA) has a protective effect against 
carcinogenesis [223]. The underlying mechanism for the BHA anticancer property is, in 
part, due to the antioxidant effect of BHA as well as upregulation of certain antioxidant 
enzymes, which can detoxify a broad range of carcinogenic compounds [224]. BHA 
along with other compounds such as phenolic antioxidants, polycyclic aromatics, and 
coumarins were later identified as inducers of these antioxidant enzymes. These 
molecules share a common property of modifying sulfhydryl groups (-SH) by oxidation, 
reduction, or alkylation [225]. A low non-lethal dose of -SH reactive inducers evokes a 
coordinated increase in antioxidant enzymes level and activity. This cellular adaptation is 
called electrophile counterattack response [226]. Based on these observations, it was 
suggested that the cellular proteins -SH group acts as a cellular sensor that reacts with 
the inducers to produce the cytoprotective counter response.  
The susceptibility of the -SH for oxidation is determined by the dissociation 
constant (Pka). At the physiological pH, the reactivity of thiol is widely varied depending 
on its Pka. Thiols with low Pka tend to exist in the thiolate anion form (S-), thus are more 
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likely to be oxidized by ROS [227, 228]. Some oxidation products of the thiols, such as 
sulfenic acids and occasionally, sulfinic acid are reversible, which provide a mechanism 
for regulation of cell signaling [229]. For instance, reversible oxidation of protein thiols 
has been shown to modulate ion channel activity [230], protein kinases [231], 
phosphatases [232], and transcription factors [233]. On the other hand, some thiol 
oxidation are irreversible, for example, sulfinic acid oxidation to sulfonic acid is 
irreversible and as such, the modified protein loses its function and is degraded [234]. 
Therefore, the reversible oxidation of the thiol groups is an important mechanism by 
which ROS can modify cell signaling that results in cytoprotection. An important thiol-
based effector for maintaining redox homeostasis is the Keap1-Nrf2 system (Figure 1.3), 
which plays an essential role against oxidative stress. Both Nrf2 and Keap1 proteins 
contain thiol group and the oxidation of both proteins are implicated in the regulation of 
this system.  
The enhanced phase II antioxidant enzyme activity is, in part, attributed to the 
increased transcription of their genes. While these antioxidant enzymes are under 
transcriptional control of the ARE, the transcriptional factors for the ARE were unknown 
until Nrf2-null mice were established in 1997 [235]. It was found that induction of phase II 
antioxidant enzyme induction by BHA was abrogated in Nrf2-null mice. The regulator of 
Nrf2 activity was soon discovered in 1999 when a new thiol rich protein was isolated and 
named Kelch-like ECH-associated protein 1 (Keap1). Thus, the Keap1-Nrf2 system is a 
two-component system where Keap1 acts as a sensor for ROS whereas Nrf2 is an 
effector for coordinated activation of antioxidant enzymes genes expression. In the 
cytoplasm, Keap1, along with Cullin3 (Cul3) form a ubiquitin E3 ligase complex and 
polyubiquitinate Nrf2, which is then degraded by the proteasome system. In unstressed 
conditions, Nrf2 is constantly degraded. However, upon ROS exposure, the -SH of 
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cysteine residues of Keap1 are modified, which results in reduced activity of the ubiquitin 
E3 ligase activity of the Keap1-Cul3 complex and Nrf2 stabilization. Nrf2 then 
translocates to the nucleus, dimerizes with the small musculo-aponeurotic fibrosarcoma 
(sMAF), binds to ARE and initiates the transcription of a battery phase II antioxidant 
enzymes genes.  
Nrf2 is a member of the mammalian cap ‘n’ collar (CNC) transcription factor 
family that contains a well-conserved basic region-leucine zipper (bZIP) motif. The CNC 
transcription factor family contains P45, Nrf1, Nrf2, Nrf3, BACH1, and BACH2. [236]. As 
its family name indicates, Nrf2 contains a basic region responsible for the DNA binding, 
and leucine zipper that mediates dimerization with sMAF protein.  
 Keap1 dependent regulation of Nrf2 
Nrf2 structure consists of multiple functional domains: Neh1 (Nrf2-ECH homology 
domain-1) to Neh6 (Figure 1.4). Different domains mediate different functions, for 
instance, Neh1 mediate DNA binding and dimerization, whereas Neh3, Neh4, and Neh5 
have a role in transcriptional activation. Nrf2 lacking Neh2 domain exhibited an 
increased transcriptional activity suggesting that there is an inhibitory molecule that 
interacts with the Neh2 domain. Two-hybrid screening analysis was used to isolate 
Keap1 as an inhibitory Neh2 interacting protein [237]. Thus, Keap1 acts as a recognition 
component of the ubiquitin E3 ligase complex and therefore creates the inducible nature 
of the Nrf2 function. Under normal conditions, Nrf2 is constitutively degraded through the 
proteasomal system, which maintains the amount and the activity of the Nrf2 at a low 
level. The underlying mechanism for Nrf2 ubiquitination in the normal, unstressed 
condition is related to the structural orientation of the Cul3-Keap1-Nrf2 complex. The 
DLG and ETGE motifs in the Neh2 domain of the Nrf2 are critical for interaction with the 
Keap1 DC domain. Each motif interacts with its own Keap1 DC domain. This conjugation 
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of Nrf2 with the keap1aligns the lysine residues between the DLG and ETGF motifs and 
facilitate Nrf2 ubiquitination by adding ubiquitin groups on lysine in the Neh2 domain of 
Nrf2 [236]. The ROS-induced modification of Keap1 cysteine residues disrupts the 
activity of the Keap1-Cul3 E3 ligase complex, which allows Nrf2 to accumulate in the 
nucleus [236]. Thus, the reactive cysteine residues render keap1 as a critical redox-
sensitive biosensor for the regulation of Nrf2.  
Keap1 deficient mice died within three weeks after birth due to malnutrition 
resulting from esophageal stenosis. The phenotypes of the Keap1-null mice and 
subsequent lethality were completely rescued by the disruption of Nrf2 [238]. Transgenic 
expression of Keap1 with mutant cysteine 273 (Cys273) or Cys288 failed to rescue the 
lethality of the Keap1 null mice indicating that Cys273 and Cys288, located in the IVR 
domain of Keap1, are essential for constitutive repression of Nrf2 activity in vivo. In 
contrast, Cys151 mutant retained the ability to repress Nrf2 activation, but it had reduced 
Nrf2 activation in response to an oxidative insult. This indicates that Cys151, located in 
the BTB domain of Keap1, mediates Nrf2 activation in response to oxidative damage 
[236]. These results collectively demonstrate the importance of cysteine residues in 
maintaining Keap1 function, such that in a quiescent condition, Nrf2 is repressed, and in 









Figure 1.3 - Schematic overview of Nrf2 pathway 
Mechanisms that has been shown to be either Keap1 dependent or independent regulates 
Nrf2. In Keap1 dependent mechanisms, modification of one or more cysteine residues results 
in Nrf2 activation and nuclear translocation where it binds to ARE and increases the 
expression of cytoprotective genes. In Keap1 independent mechanisms, Nrf2 is regulated at 
the transcriptional level (1), by coactivators or other transcriptional factors such as NF-κB. At 
posttranscriptional level (2) by miRNAs. Post-transcriptional mechanisms (3) via Nrf2 
phosphorylation (P), and ubiquitination (Ub). Post-translational modification affects Nrf2 
differently; (PKC, MAPK, ERK) affects Nrf2 interaction with Keap1; (GSK3β/βTrCP) induce Nrf2 
nuclear export and ubiquitination. A number of proteins, such as P21, have been identified to 












Figure 1.4 - Domain structures of Nrf2 and Keap1  
Nrf2 has six domains, Neh1 to Neh6. Nrf2 interacting molecules are shown in green boxes above 
their interacting domain. Keap-1 has three domains; DRG domain that mediate interaction with 
Nrf2, BTB and IVR that mediate homodimerization and CUL3 interaction. 
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Keap1 independent regulation of Nrf2  
Phosphorylation of Nrf2 is one of the main mechanisms for the Keap1 
independent Nrf2 regulation. Nrf2 contains several serine, threonine, and tyrosine 
residues which can be phosphorylated by various kinases such as glycogen synthase 
kinase 3 β (GSK3β), AKT, PKC, ERK and MAPK [239]. These kinases differentially 
regulate Nrf2 with some kinases activating Nrf2, whereas others facilitate Nrf2 
degradation.  
Oxidative stress has been shown to activate GSK3β, which subsequently 
phosphorylates a member of the src family protein (Fyn), resulting in the accumulation of 
p-Fyn in the nucleus and subsequent phosphorylation of Nrf2 at tyrosine 568 residue. 
Phosphorylated Nrf2 interact with exportin-1 and exported outside the nucleus [240]. 
Furthermore, GSK3β has been shown to phosphorylate directly the Neh6 domain, which 
creates a motif that is recognized by β-transducin repeat-containing protein (β-TrCP) 
and therefore targets Nrf2 for ubiquitin-proteasome degradation [241]. Mice subjected to 
five intraperitoneal injections of the GSK3β inhibitor, SB216763, exhibited an increase in 
Nrf2 protein levels in the liver and hippocampus. More importantly, in the hippocampus 
of mice with conditional neurons specific depletion of GSK3β, the Nrf2 protein level was 
increased [242]. GSK3β therefore, is considered a key regulator of Nrf2 and may act as 
a common downstream effector of some Nrf2 inducers. For instance, in mouse 
embryonic fibroblast cells lacking Keap1, the Nrf2 inducer, nordihydroguaiaretic 
acid (NDGA) activated Nrf2 through activation of AKT, ERK and MAPK kinases, which 
lead to inhibitory phosphorylation of GSK3β, resulting in substantial reduction of Nrf2 
phosphorylation and degradation [243]. Furthermore, mice treated with dimethyl 
fumarate (DMF) by oral gavage for 3 weeks increased Nrf2 in hippocampus by inhibition 
of GSK3β via stimulation of PI3K/AKT signaling pathway [244]. Another kinase pathway 
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that has been implicated in Nrf2 activation is PKC, which has been shown to 
phosphorylate Nrf2 at Ser-40, leading to its dissociation from Keap1 [245]. However, a 
Nrf2 Ser-40 mutant could not be phosphorylated by PKC and Nrf2 remained associated 
with Keap1. Furthermore, the phosphorylation and subsequent dissociation of Nrf2 from 
Keap1 was abolished by PKC inhibitors [246].  
In addition to phosphorylation, other post transcription modifications contribute to 
the regulation of Nrf2. Intranuclear proteins (co-activators) may increase or decrease 
Nrf2 binding to ARE by interacting with Nrf2 and tethering it to the transcriptional 
machinery or by chromatin remodeling that facilitates assembly of the transcriptional 
initiation complex. For instance, CREB binding protein (CBP) has been shown to act as 
a co-activator of Nrf2 in the nucleus and is also able to promote Nrf2 acetylation of lysine 
residues within Neh1 binding domain of Nrf2, resulting in enhanced ARE binding activity 
in vitro [247]. Additionally, micro RNAs (miRNAs) have been demonstrated to be 
involved in Nrf2 regulation.  Our lab has previously shown that six weeks after 
myocardial infarction, Nrf2 was downregulated in the heart, and paradoxically, the 
transcription of Nrf2 was increased. Several miRNAs including microRNA-27a, 
microRNA-28-3p, and microRNA-34a were upregulated in the left ventricle of the 
infarcted hearts suggesting that increased local myocardial infarction-induced 
upregulation of MiRNAs may contribute to inhibition of Nrf2 translation [248]. The 
presence of an ARE binding site in the promoter of Nrf2 is suggestive of the ability of 
Nrf2 to regulate its own transcription. In accordance with this, direct binding of Nrf2 to its 
promoter region was demonstrated in murine keratinocytes using chromatin 
immunoprecipitation assay. Furthermore, the overexpression of Nrf2 increased the 
activity of a luciferase reporter assay, whereas mutant Nrf2 repressed the activity of the 
luciferase reporter [249]. This evidence that Nrf2 activates its own transcription is 
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suggestive of a positive feedback loop, leading to enhanced cell defense. Also, negative 
regulatory feedback between Nrf2 and Keap1 exists; the Keap1 promoter contains a 
binding sequence for Nrf2, thus Nrf2 regulates Keap1 by controlling its transcription, 
whereas Keap-1 controls Nrf2 via proteasomal degradation [250].   
Cross talk  
Nuclear factor k-light-chain-enhancer of activated B cells (NF-κB) is a redox-
sensitive transcription factor that contributes to the regulation of the Nrf2 pathway. In 
unstressed cells, (NF-κB) is primarily located in the cytoplasm bound to its inhibitor IκB. 
NF-κB inducers such as Ang II, TNF and H2O2  can stimulate IκB kinase, which results in 
dissociation of NF-κB and its translocation to the nucleus [251]. Under normal 
conditions, an interplay between Nrf2 and NF-κB provides a coordinated response to 
oxidative stress to confer cellular protection. However, in several chronic diseases 
including CHF, the interplay often leads to an opposite effect such that Nrf2 is, in 
general, downregulated whereas NF-κB is hyper-activated. Nrf2 downregulation is 
attributed, at least in part, to hyper-activation of NF-κB, which can inhibit Nrf2 expression 
in several ways; NF-κB competes with Nrf2 for creb binding protein (CBP) binding in the 
nucleus thus preventing Nrf2 binding to ARE, also, NF-κB recruit histone deacetylase 3 
(HDAC3), which has been shown to compete with Nrf2 for binding with sMAF [252]. On 
the other hand, Nrf2 has been implicated in the regulation of NF-κB via attenuation of 
IκB phosphorylation. For instance, NF-κB activation, as well as pro-inflammatory 
cytokines are increased in the lung of  Nrf2 knock out mice [253]. Furthermore, Nrf2 
antagonizes pro-inflammatory genes expression such as interleukin 6 (IL6) and 
interleukin 1 β (IL-1β) [254]. As such, in addition to the classical antioxidant function, 
Nrf2 has an anti-inflammatory function attributed, in part, to crosstalk with NF- κB and 
direct regulation of pro-inflammatory genes. 
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Cross-talk with autophagy is another proposed mechanism that contributes to the 
regulation of Nrf2 in the Keap1 dependent pattern [255]. An increase p62, which is a 
cargo receptor for selective autophagy directly interacts with Keap1, which enables p62 
to compete with Nrf2 for Keap1 binding and thus activation of Nrf2 and increased Nrf2 
target gene transcription [236]. Furthermore, mutant p62 overproduction, which loses its 
ability to bind with Keap1, did not affect Nrf2 activation, indicating that the upregulation 
of Nrf2 by p62 is Keap1 dependent [256].  
Nrf2 activators  
Almost all currently known Nrf2 activators are inhibitors of Nrf2-Keap1 interaction 
and they are believed to react with the -SH of cysteines in the Keap1 by oxidation or 
alkylation [236, 245], which alters the conformation of Keap1, resulting in a cessation of 
Nrf2 ubiquitination. Currently, Nrf2 activators are classified into ten classes based on 
their chemical structure and the nature of reaction with cysteine sulfhydryl groups. 
Regardless of chemical structure, all Nrf2 activators share a common feature of forming 
a covalent adduct with Keap1 cysteine residues with different potency and specificity 
[257]. Covering all Nrf2 activators is beyond the scope of this dissertation, however, the 
two activators which are relevant to the current work include exercise training and 
curcumin which will be discussed below.   
Exercise  
There is increasing evidence indicating that Nrf2 plays a key role in how oxidative 
stress mediates the beneficial effects of exercise training [258, 259]. ROS generation 
during physical exercise induce endogenous antioxidant enzymes that, to a great extent, 
are regulated by Nrf2. Regular aerobic ExT in rodents has consistently been shown to 
activate Nrf2 signaling across several tissues including the brain [260] skeletal muscle 
[261], myocardium [262], kidney [263], and liver [264]. The exercise-induced 
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upregulation of Nrf2 is necessary for the ExT-induced adaptation. For instance, after 5 
weeks of treadmill ExT, mice deficient in Nrf2, showed reduced exercise capacity, 
mitochondrial biogenesis and antioxidant enzymes in skeletal muscle [259]. More 
importantly, ExT can restore Nrf2 levels in conditions where Nrf2 signaling is already 
impaired. Reduced Nrf2 level in the myocardium of old (23 months) mice was restored 
after 8 weeks of moderate-intensity exercise[262].   
Inflammation appears to be largely responsible for Nrf2 dysregulation in CHF via 
activation of pro-inflammatory cytokines and their downstream mediators such as NF-κB. 
Sustained inflammation activates GSK-3β, a kinase that plays a role in Nrf2 degradation 
[265]. ExT may impact these pathways since it has been shown that ExT reduces pro-
inflammatory cytokines [266], NF-κB expression [133]. ExT is also associated with 
activation of the AKT-PI3K signaling pathway, which inhibits GSK-3β, thus preventing 
Keap1-independent degradation of Nrf2 [236, 267].  
Curcumin  
Natural products have historically proven their value as a source of molecules 
with therapeutic potentials. Clinical pharmacological studies of these natural products, 
which were predominantly derived from plants, were the basis for some of the commonly 
used medicines such as aspirin and morphine [268]. Such utility was recognized on a 
larger scale as the discoverer of artemisinin, a natural product discovered from a 
traditional Chinese medicine, shared the Noble Prize in Physiology and medicine in 
2015. Artemisinin was developed into an effective therapy for Plasmodium falciparum 
malaria [269]. Naturally occurring polyphenols such as curcumin and resveratrol have 
gained importance because of their abundance, low cost, and minimal side effects  
Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene3,5-dione) is a 
constituent of the traditional medicine known as turmeric. Major constituents of turmeric 
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are diarylheptanoids (collectively known as curcuminoids) which make up approximately 
5% of the turmeric. Curcuminoids extract contains three major compounds: curcumin 
(60-70%), demethoxycurcumin (20%), and bisdemethoxycurcumin (10%). Mounting 
evidence from preclinical studies over the past few decades have shown that curcumin 
has a wide variety of beneficial biological activities such as anticancer, anti-
inflammatory, and antioxidant properties [270-273], these findings have led to more than 
120 clinical studies of curcuminoids against several diseases. The attractiveness of 
curcumin as a therapeutic agent is further enhanced by its safety up to 20 mg per 
serving [270].  
Animals and human studies indicate that systemic bioavailability of curcumin is 
relatively low (less than 1%) after oral administration. For instance, after 8 g of oral 
curcumin administration, the peak serum concentration was detected after 1 hour at 1.75 
μM/L [274]. Furthermore, curcumin is extensively conjugated in the intestine and liver to 
form curcumin glucuronide, curcumin sulfate or reduced to tetrahydrocurcumin, 
hexahydrocurcumin, and octahydrocurcumi, these modifications further contribute to low 
bioavailability of curcumin[275]. There is some evidence indicating that oral 
administration of curcumin accumulates in gastrointestinal tissues and was detected in 
both malignant and normal colorectal tissues [276], suggesting that oral administration of 
curcumin is not effective for its delivery to tissues outside the gastrointestinal tract. 
Several curcumin formulations are currently being explored with the aim of increased 
bioavailability and targeted delivery. Examples of these approaches include 
encapsulation to nanoparticles, liposomes, and micelles [277].   
Curcumin is an effective scavenger of NO• and O2•– in the cell-free system [278, 
279]. In skeletal muscles (L-6 myoblast), curcumin treatment reduced intracellular ROS 
measured by dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay. [280], indicating 
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that curcumin diffuses through the cell membrane and prevents the production of 
different ROS compounds required to oxidize DCFH-DA. In humans with colorectal 
cancer, orally administered curcumin (3600 mg) daily for 1 week significantly reduced 
malondialdehyde-DNA adduct, which reflects oxidative DNA damage in the intestinal 
mucosa [281]. In addition to the direct antioxidant property, curcumin has been shown to 
induce the expression of phase II antioxidant enzymes [282]. In particular, curcumin 
increases the expression of phase II antioxidant enzymes via activation of Nrf2. For 
instance, in rat renal tubular epithelial cells, curcumin treatment increased expression of 
Nrf2 and HO-1, whereas Nrf2 knockdown with small interfering RNA (siRNA) prevented 
the curcumin-induced upregulation of HO-1 [283]. Furthermore, in mice with ethanol-
induced liver injury, oral curcumin (150 mg/kg) for 6 weeks resulted in an increased 
expression of Nrf2, which was associated with upregulated antioxidant enzymes and 
reduced hepatic malondialdehyde [284]. Curcumin has also been shown to possess a 
neuroprotective effect, which was associated with Nrf2 upregulation in mice with cerebral 
ischemia [285], and has been found to prevent or reduce certain pathological features of 
Alzheimer's disease in animals and human [286, 287].  
In addition to its antioxidant effects, curcumin has been shown to inhibit multiple 
mediators of the inflammatory response. As mentioned above, curcumin reduces 
oxidative stress by reduction of malondialdehyde-DNA adduct, which is immunogenic 
and initiates a pro-inflammatory response. Furthermore, the anti-inflammatory effect of 
curcumin results from its ability to inhibit NF-κB pathway, as well as other pro-
inflammatory signaling pathways [288].   
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Curcumin processes several distinct chemical properties that facilitate its 
biological effects (figure 1.5). The hydrogen bond donation capacity of β-dicarbonyl 
moiety, hydroxy phenolics, and methoxy groups facilitate the interaction of curcumin with 
amino acid residues in different protein targets. The ability of curcumin to interact and 
inhibit DNA methyltransferase is relevant to the anticancer effect of curcumin [275]. On 
the other hand, the β-dicarbonyl moiety of the curcumin is thought to be responsible for 
its antioxidant effect. For instance, molecules with an extra pair of electrons such as 
thiols are covalently attached to the β-unsaturated dicarbonyl segment of the curcumin 
[280]. As such, the covalent binding of curcumin with thiols containing proteins such as 
Keap1 and subsequent Nrf2 activation likely contribute to the curcumin antioxidant 
property.  
 
Statement of the problem 
Figure 1.5 - Structure of curcumin and its key function groups 
Blue circle depicts polyphenol, green circles depict Micheal acceptor sites, and red circles 
depict hydrogen binding sites.  
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 There is substantial evidence that ROS is increased in CHF and contribute to the 
disease progression [107]. Ang II generated within the CNS as well as peripheral Ang II, 
acting via circumventricular organs, increases ROS levels within the RVLM and at sites 
that project to the RVLM, which evoke oxidative modification of neuronal constituents 
such as ion channels, resulting in overactivation of sympathetic neurons [11]. Global 
sympathoexcitation further damage cardiomyocytes, which leads to further increases in 
the discharge sensitivity of presympathetic neurons within the RVLM creating a vicious 
positive feedback cycle [58, 289].  
 One of the peripheral sequelae of the overactivation of the SNS is peripheral 
vasoconstriction, which in the long term, becomes exaggerated and results in many 
adverse skeletal muscle adaptations[290]. Such a state of chronic under perfusion, 
especially during exercise, leads to a greater reliance on anaerobic metabolism and 
increased oxidative stress[193]. Oxidative stress in skeletal muscle alters the 
sensitization of nerve endings within skeletal muscle and further exacerbates SNS 
overactivation leading to peripheral vasoconstriction creating another positive feedback 
cycle. Furthermore, Increased ROS levels in skeletal muscle is associated with muscle 
wasting and dysfunctional contractile machinery, which substantially contribute to 
exercise intolerance [190]. 
Extensive work over the past two decades has identified Nrf2 as a key signaling 
intermediate of several antioxidant enzymes and oxidative stress in multiple cell types 
including neurons and skeletal muscle [265, 291]. Furthermore, reduced antioxidant 
capacity in the RVLM and skeletal muscle substantially contribute to sympathoexcitation 
and exercise intolerance [132]. While the beneficial effects of ExT in CHF are largely 
attributed to its antioxidant effects, it is not known whether ExT is associated with the 
upregulation of Nrf2 in the RVLM neurons in CHF condition. Furthermore, it is not clear 
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whether the reduced Nrf2 expression in skeletal muscle contributes the exercise 
intolerance in CHF. Therefore, we tested the hypothesis that in CHF, ExT increases 
the expression of Nrf2 within the RVLM, which increased the expression of 
antioxidant enzymes and reduces sympathoexcitation. Furthermore, we 
hypothesized that in CHF, Nrf2 is reduced in the skeletal muscle, which 
contributes to reduced antioxidant enzymes expression and exercise intolerance. 
Finally, we hypothesized that upregulation of Nrf2 by curcumin would increase the 
expression of antioxidant enzymes in the skeletal muscle and improved exercise 
performance. 
Significance of the study  
 
 Nuclear Factor E2-related Factor 2 (Nrf2) is well-known regulator of phase II 
antioxidant enzymes, but its functional role has not been extensively assessed with 
regard to the modulation sympatho-excitation and exercise intolerance in CHF. The 
studies below suggest that impaired Nrf2 signaling is a critical mechanism underlying the 
enhanced oxidative stress in the RVLM and the skeletal muscle of mice with CHF. ExT 
reduces sympathoexcitation, and curcumin prevents the decline in the exercise 
performance in CHF mice by upregulation of antioxidant defenses in the RVLM and 
skeletal muscle respectively, likely mediated by activation of Nrf2 signaling. These 
studies suggest that rather than therapeutically blocking oxidative stress, it is possible to 
focus on therapeutics that upregulate Nrf2 in order to induce the production of 
antioxidant enzymes. As such, these findings suggest a novel potential therapeutic 
target for the reduction of sympathoexcitation and for the improvement of exercise 





 To address our hypothesis, we carried out a series of in vivo physiological 
cardiovascular experiments and biochemical studies. We utilized a CHF male mouse 
model achieved by permanently ligating the left anterior descending artery at 
approximately 8 weeks of age. This model is relevant to acute MI patients who do not 
receive timely or successive reperfusion.  
 In order to determine exercise capacity and carry out ExT, we utilized a motor 
driver treadmill, which is superior to other modalities such as swimming and running 
wheel voluntary exercise. Swimming is not a nature of mice behavior and it is difficult to 
define objective exhaustion criteria and the amount of work done. While the amount of 
work can be quantified on both a treadmill and a running wheel, it is difficult to control 
the amount of work in a running wheel, as mice are exercising voluntarily and CHF mice 
may not be able to or desire to run on their own [292].   
Specific aims 
Aim 1: Determine whether reduced Nrf2 signaling in the RVLM contributes to 
sympathoexcitation in CHF mice. 
Aim 2: Identify the role of ExT on the regulation of Nrf2 in the RVLM of CHF mice 
and its impact on sympathoexcitation. 
Aim 3: Investigate whether suppressed Nrf2 signaling in skeletal muscle 
contributes to exercise intolerance in CHF mice. 
Aim 4: Determine whether curcumin (Nrf2 activator) improves exercise capacity 
in mice with CHF.   
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Each objective will be introduced in the subsequent chapters, with each chapter contain 
a brief introduction, detailed method and discussion of major findings. A final 
comprehensive discussion will follow, which will provide a cohesive overview of major 




















CHAPTER II: EXERCISE TRAINING UPREGULATES Nrf2 
PROTEIN IN THE ROSTRAL VEMTROLATERAL 



























 As mentioned in the preceding section, ROS are increased, whereas the 
expression and activity of antioxidant enzymes are reduced in the RVLM of animals with 
CHF [113, 133]. Because oxidative stress in RVLM neurons results in a state of neuronal 
sensitization and enhanced excitability [58], the decreased expression [133] and activity 
[293] of the antioxidant enzymes in the RVLM may be a key mechanism by which 
sympathoexcitation occurs in CHF. However, it remains to be seen what upstream 
mechanisms mediate altered expression of the antioxidant defense system in RVLM 
neurons in the CHF state.   
  Nuclear factor erythroid 2–related factor 2 (Nrf2) plays a key role in mediating 
the transcriptional regulation of many antioxidant enzymes [254]. In a recent study [132], 
our lab found that selective deletion of the Nrf2 gene in the RVLM of normal mice 
resulted in downregulation of HO-1, NQO1, SOD2, and catalase protein expression and 
an elevation of superoxide and ROS in the RVLM. These mice also display a sustained 
increase in blood pressure, sympathoexcitation, and impaired baroreflex function. 
Furthermore, in CHF mice, Nrf2 upregulation in the RVLM enhanced NQO1, and HO-1 
expression reduced sympathetic nerve activity and improved baroreflex function [294]. 
These studies suggest that Nrf2 may be an important target for autonomic modulation in 
the CHF condition.  
 Mounting evidence indicates that ExT normalizes sympathetic outflow and 
arterial baroreflex function in CHF [155, 295, 296]. These beneficial effects are 
accompanied by upregulation of antioxidant enzyme expression in the RVLM [133]. 
However, the precise mechanism that converts the act of ExT into a change in the 
expression of antioxidant enzymes in the RVLM remains to be elucidated. Furthermore, 
increasing evidence indicates that Nrf2 signaling plays a key role in how oxidative stress 
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mediates the beneficial effects of ExT. Regular ExT evokes an episodic increase in 
oxidative stress, leading to the upregulation of endogenous antioxidant defenses and 
overall greater ability to counteract oxidative stress [258]. These findings provide further 
rationale for Nrf2 modulation in RVLM in response to ExT.  
We, therefore, aimed to investigate the effect of ExT on Nrf2 expression in the 
RVLM in the CHF state. We hypothesized that ExT increases Nrf2 expression, 
which subsequently increases antioxidant enzymes and reduces sympathetic 





































 All animal experiments in this study were approved by the Institutional Animal 
Care and Use Committee at the University of Nebraska Medical Center. These 
experiments were carried out under the guidelines of the National Institute of Health 
Guide for the Care and Use of Laboratory Animals. 
 C57BL/6J mice were purchased from Jackson laboratory (Bay Harbor, ME) at 8 
weeks of age and allowed to acclimate at the University of Nebraska Medical Center 
animal facility for one week. Food and water were provided ad libitum, and the mice 
were maintained on a 12:12-h light-dark cycle. For induction and maintenance of 
anesthesia, isoflurane (2%) was administered via inhalation, and Buprenorphine (0.05 
mg/kg) was provided on the day of surgery and for 3 days post-surgery to reduce pain. 
Because almost all published studies regarding the effect of ExT on cardiovascular 
disease have utilized male mice, we chose this gender, which allows for comparison with 
the current literature. We recognize however, that there may be sex differences in 
response to ExT [297, 298]. 
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 Because of the small amount of RVLM tissue available from individual animals, 
multiple cohorts were used in this study (Table 2.1), which can be summarized as 
follows: morphological and Nrf2/NQO-1 immunoblotting data (Sham-Sed, n = 6; Sham-
ExT, n = 5; CHF-Sed, n = 6; CHF-ExT, n = 4); Nrf2 and NQO-1 mRNA data (Sham Sed, 
n = 6; Sham-ExT, n = 6; CHF-Sed, n = 5; CHF-ExT, n = 6); echocardiography data 
(Sham-Sed, n = 5; Sham-ExT, n = 6; CHF-Sed, n = 6; CHF-ExT, n = 5); hemodynamic 
data (Sham-Sed, n = 5; Sham-ExT, n = 6; CHF-Sed, n = 6; CHF-ExT, n = 7). 
 







1 • Sham Sed  
• Sham ExT  
• CHF-Sed  
• CHF-ExT  
 
• Nrf2 protein 
expression in the 
whole brain stem 
• Citrate synthase 
in soleus muscle   
 
2 • Sham Sed  
• Sham ExT  
• CHF-Sed  
• CHF-ExT  
 
• Nrf2 and NQO-1 
mRNA in the 
RVLM punches  
 
3 • Sham Sed  
• Sham ExT  
• CHF-Sed  
• CHF-ExT 
 
• Nrf2 and NQO-1 
protein 
expression in the 
RVLM punches   
• Urine NE 
excretion 
• Plasma NE 
 
4 • Sham Sed  
• Sham ExT  








Model of CHF  
Chronic HF was induced by permanent left anterior descending coronary artery 
ligation, as previously described [76]. Briefly, under 2% isoflurane anesthesia, mice were 
intubated and ventilated using a mechanical respirator (Mouse Ventilator miniVent model 
845, Harvard Apparatus; tidal volume: 150 ul; frequency: 200 breaths/min) throughout 
the surgery. A thoracotomy was performed between the 4th and 5th intercostal space to 
expose the heart. In the CHF group, the left anterior descending branch of the coronary 
artery was permanently ligated with 7-0 suture. After these procedures, the lungs were 
re-inflated, the chest was closed with 6-0 suture, and the skin was closed with 4-0 
suture. Sham mice underwent the same procedures, but the coronary artery was not 
ligated. Once the animals began to recover from anesthesia, the trachea was extubated. 
Mice were then placed on a 30-32 °C heating pad and room air was supplemented with 
100% oxygen (1L/min into the cage) for 3 days after the surgery to improve survival rate. 
Mice were assigned randomly into four groups: Sham Sedentary (Sham-Sed), sham 
exercise-trained (Sham-ExT), CHF sedentary (CHF-Sed), and CHF exercise-trained 
(CHF-ExT). Infarct size was determined postmortem by tracing the scar area and the 
whole left ventricle (LV) using ImageJ software [National Institutes of Health (NIH), 
Bethesda, MD]. 
Echocardiography  
Four weeks after MI or sham surgery, echocardiography was carried out on all 
mice. Using a 40 MHz probe, hearts were imaged on a Visual Sonics Vevo 3100 
ultrasound. B-mode images were acquired in the long and short axis under isoflurane 
anesthesia (1-2%). All animals were echoed when heart rates were above 400 bpm. Left 
ventricular volumes and diameters were measured. Ejection fraction (EF) was calculated 
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by a standard formula ((LVEDV-LVESV)/LVEDV) × 100. Fractional shortening (FS) was 
calculated as ((LVEDD-LVESD)/LVEDD) × 100.  
Maximal Exercise Capacity Testing  
Figure 2.1A shows the general study design. After a 1-week acclimatization 
period, the mice were echoed and underwent either sham or myocardial infarction 
surgery. Four weeks after surgery, the mice were echoed again and subjected to an 
exercise capacity test followed by aerobic training on a treadmill. After 8 weeks of 
training, the mice were echoed and subjected again to exercise capacity test to evaluate 
the change in exercise capacity.    
Figure 2.1B shows the exercise capacity testing protocol. We performed exercise 
familiarization and capacity testing as previously described [299], with minor 
modifications. Mice were familiarized with a motorized treadmill (Columbus Instruments, 
Columbus, OH). Familiarization consisted of a 10 min period where the treadmill and 
speed were set to zero with the shock grid setting at 1.2 mA and 2 Hz. The treadmill 
speed was then increased to 6 m/min on the next day for an additional 10 minutes. On 
the following day, mice were subjected to an exercise capacity test, which consists of a 
warm-up period at a speed of 6 m/min for 6 min. The speed was increased by 3 m/min 
every 3 min at 5% inclination until exhaustion. At the termination of the test, the total 
distance and the peak workload were recorded. Based on the peak workload, individual 
workloads corresponding to 60% of the maximum speed were determined. 
 We developed strict criteria for exhaustion. These criteria include 1) 5 
consecutive seconds on the electric grid without re-engaging the treadmill; 2) Inability to 
keep up with the treadmill speed for 3 minutes. Every mouse was removed from his lane 
once one or both criteria was reached. Following 8 weeks of training, we repeated this 
test to evaluate changes in exercise capacity. Distance run (meters run before 
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exhaustion) and work performed (calculated as the product of body weight and vertical 
distance) were recorded. The vertical distance was calculated as the product of the 
distance run and the angle of inclination of the treadmill as outlined previously [300]. 
Exercise training 
Mice assigned to exercise training groups were subjected to 8 weeks of treadmill 
running at 60% of the maximal workload achieved during the initial exercise capacity 
test. As shown in figure 2.1C, the training protocol consisted of a warm-up period at 6 
m/min for 5 minutes. The training intensity was set at 14 m/min for the Sham ExT group 
and 11 m/min for the CHF ExT. These intensities corresponded to 60% of the maximal. 
Because exercise capacity is different in each mouse, and given that exercise 
adaptations occur at an intensity corresponding to maximal lactate steady state (60% of 
maximal speed), we chose to train each group at their average 60% of maximal speed 
rather than similar absolute speed [301-303]. Speed was calculated for each group 
during the initial exercise capacity test. A recent exercise guideline paper published this 
year further supports this concept [292] Training sessions occurred between 16:00 and 
18:00 hours, 5 days per week. Sedentary mice were habituated to the experimental 
environment on the treadmill at 0 speed two to three days per week.  
Blood lactate measurements  
  Venous blood lactate concentrations were obtained from the tail vein after mice 
were acclimated to tail vein blood collection. Prior to the testing, ~0.7μL of blood (via tail 
vein prick) was collected and placed for analysis on a handheld lactate meter (Lactate 
Plus; Nova Biomedical, Waltham, MA, USA). Within one minute of test completion, 
~0.7μL of blood was again collected and analyzed.  
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Hemodynamics and baroreflex measurements 
Under 2% isoflurane anesthesia, mice were placed on a metal heating pad in the 
supine position. The appropriate level of anesthesia was determined by the absence of 
reflex withdrawal to a painful stimulus such as foot pinch. The right common carotid 
artery was dissected, and a pressure transducer (SPR-1000; Millar Instruments, 
Houston, TX) was advanced into the ascending aorta and left ventricle for the 
measurement of blood pressure (BP), left ventricular pressure (LVP), the first derivative 
of LVP (dP/dt) and heart rate (HR). All signals were processed by a PowerLab data 
acquisition system (Model 8S) and analyzed using LabChart 7 software (ADInstruments, 
Colorado Springs, CO). The transducer was then pulled back into the aorta and left in 
place to record arterial pressure. The left jugular vein was cannulated for intravenous (iv) 
injections. Phenylephrine was administrated (0.2 μg/μL in 20–40 μL, IV) to increase 
arterial pressure and the subsequent bradycardia was recorded.  
Construction of baroreflex curves  
The induced arterial baroreflex sensitivity (IBRS) was analyzed by logistic 
regression over the entire pressure range after phenylephrine administration. The values 
of BP and HR were acquired every 2 seconds from the threshold to the saturation points. 
A sigmoid logistic regression curve was fit to the data points using the following 
equation: HR = A/1 + exp[B(MAP − C)] + D where A is the HR range, B is the slope 
coefficient, MAP is the mean arterial pressure, C is the pressure at the midpoint of the 
range (BP50), and D is the minimum HR [304]. The peak slope (or maximum gain) was 
determined by taking the first derivative of the baroreflex curve and was calculated with 




Figure 2.2 shows the mathematical and graphical expression of the model used 
to describe the arterial baroreflex by relating in a logistic form the mean arterial pressure 
response and HR response. The parameters are A, range of the HR response; B, the 







Figure 2.1 - Study design, exercise testing, and training protocols 
A: Schematic of general study design. B: incremental exercise capacity testing protocol. C: 
exercise training regimen including warm-up, exercise intensity, duration, and cool down. 




















Figure 2.2 - A model of the arterial baroreflex 





RVLM punches  
 The RVLM nuclei were isolated by microdissection of brain sections with a hollow 
blunt needle using the following coordinates: 0.75 to 1.75 mm rostral to the obex, 1.25 
mm lateral to the midline [305] (Figure 2.3). The RVLM punches were removed and 
stored at −80°C for subsequent biochemical measurements.  
mRNA expression  
  Total RNA was extracted using TRIZOL reagent (Invitrogen) from RVLM 
punches. RNA was reverse transcribed into double-stranded cDNA using an iScript 
cDNA synthesis kit (Bio-Rad Laboratories). cDNA templates (50 ng) were then subjected 
to a real-time polymerase chain reaction in triplicate using a thermocycler (PTC-200 
Peltier thermal cycler with CHROMO4 continuous fluorescence detector; Bio-Rad 
Laboratories), and Brilliant III ultra-FastQPCRmastermix (Agilent Technologies). Mouse 
Nrf2 primers (Mm.PT.58.29108649) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH; Mm.PT.39a.1) from the Integrated DNA Technologies (Coralville, Iowa) were 
used for semi quantification of Nrf2 mRNA expression. Nrf2 mRNA was normalized to 
GAPDH mRNA as Δ cycle, and then the relative expression was compared with the 
control group using ΔΔ cycle threshold method for quantification with Opticon Monitor 
software (Bio-Rad laboratories). 
Western blot analysis 
The target proteins and their antibodies were Nrf2 (ab62352 R-IgG) and NQO-1 
(ab 80588 R-IgG). GAPDH (Thermo 15738 M-IgG) served as an internal loading control. 
Total protein was extracted using RIPA buffer. Protein concentration was measured 
using Pierce BCA protein assay kit (Thermo 23225). The protein concentration was then 
adjusted by adding 4% sodium dodecyl sulfate buffer to obtain equal concentration 
among the samples. 30 μg protein from each sample was loaded on a 10% SDS-PAGE 
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gel before being subjected to electrophoresis. The gel was then transferred onto a 
Polyvinylidene Difluoride (PVDF) membrane. The membrane was probed with the 
primary antibodies of the target proteins and then with GAPDH primary antibody. After 
primary antibody incubation, the membrane was probed with the secondary antibodies 
followed by treatment with chemiluminescence substrate (Pierce). A UVP BioImaging 
System (Epi Chemi II Darkroom, Analytik Jena US LLC, Upland, CA) was used to 
visualize and analyze the protein bands. The data are presented as the target proteins 































Figure 2.3 - RVLM micro-punches 
A: Gross mouse brain showing the obex location after removal of the cerebellum 
B: Schematic sagittal and coronal mouse brain, taken from the Paxinos and Watson mouse atlas, 
showing the location of the RVLM 




Nrf2 antibody validation using a blocking peptide  
Because Nrf2 is highly translationally modified, we felt it necessary to validate the 
Nrf2 antibody. The Nrf2 antibody was diluted in the blocking buffer (1:1000; 10 ml) which 
was equally divided into two tubes, 5 ml each. In the first tube, 2 times excess blocking 
peptide (ab 167152) was added (10 ul), in the second tube, an equivalent amount of 
buffer only was added. RVLM punches samples (n = 3) from normal C57BL/6 mice were 
loaded on the first 3 lanes on a 10% SDS-PAG gel, the same samples were loaded 
again on the next 3 lanes before subjected to electrophoresis. After the gel was 
transferred into Polyvinylidene Difluoride (PVDF) membrane, the membrane was cut into 
two halves; the first half, containing the 1st three lanes was incubated with the control 
unblocked antibody, the second half of the membrane, containing identical samples was 
incubated with the blocked antibody. The two membranes were probed with the 
secondary antibodies followed by treatment with chemiluminescence substrate (Thermo 
Fisher Scientific Inc, Rockford, IL). A UVP BioImaging System (Epi Chemi II Darkroom, 
Analytik Jena US LLC, Upland, CA) was used to visualize and analyze the protein 
bands. The data are presented as the target proteins band densities divided by the 
GAPDH density. 
Urinary NE 
 Mice were placed in metabolic cages (Harvard Apparatus, Holliston, MA) and 
acclimated to the environment for 2-3 days. Urinary NE concentration was measured 
using a NE Enzyme Immunoassay kit (Labor Diagnostika Nord KG, Nordhorn, 
Germany). The samples were diluted 20-fold, from which 10 ul was used for NE 
measurement according to the kit instructions. The sensitivity and the standard range  
are 1.7 ng/ml and 5-1000 ng/ml, respectively. Each sample was measured in duplicate. 
64 
 
The excretion rate was calculated by multiplying NE concentration by the 24-hour urine 
volume.  
Plasma NE 
 Blood was collected by cardiac puncture following the acute experiment. Under 
2% isoflurane anesthesia, the heart was exposed via a thoracotomy by removing the 
ventral segment of the 3rd to 6th ribs together with the sternum. A 21G needle 
connected to 1 mL syringe was inserted into the left ventricle. Blood was withdrawn 
slowly and transferred into a 1.5 mL Eppendorf tube containing 10% K EDTA (10 μl). 
Blood was centrifuged at 1000 X g for 10 min at 4 °C. We were able to reliably obtain ∼1 
mL blood which resulted in ∼500 μL of plasma, from which 300 μL was used to measure  
the NE concentration. The sensitivity and the standard range are 0.036 ng/ml and 5-
1000 ng/ml, respectively. 
 Citrate Synthase 
Citrate synthase (CS) activity was carried out as previously described [306]. 
Briefly, left soleus muscle samples were placed on ice-cold lysis buffer (MSM-EDTA) 
buffer, homogenized and centrifuged at 14000 x g for 10 minutes. The supernatants 
were collected and protein concentration was measured using the Pierce bicinchoninic 
acid method (Thermo Fisher Scientific Inc, Rockford, IL). The assays were carried out in 
duplicate using a spectrophotometer (DU Series 640; Beckman Instruments, Fullerton, 
CA). The CS activity was determined by measuring the appearance of yellow product 
((5,5`-dithiobis [2-nitrobenzoic]; DTNB), which was detected spectrophotometrically by 
measuring absorbance at 412 nm. The absorbance changes were measured every 15 s 
over 1 min at 412 nm for determination of the CS activity. The CS activity of each 
specimen was expressed as specific activity normalized to total protein (micrograms). 
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Statistical analysis   
All data are expressed as mean ± SEM. Ordinary 2-way ANOVA was used to 
perform between-group comparisons. To perform within-group comparisons, repeated 2-
way ANOVA analysis was used. Tukey’s post hoc test was used for analyzing the 
difference among the 4 groups using GraphPad Prism 7.03 software. A P value of < 0.05 










































Bodyweight, organs weight, and morphological data 
The morphological data shown in Table 2.2 are from the cohort used to measure 
Nrf2 and NQO-1 proteins in RVLM punches (Sham-Sed, n= 6; sham-ExT, n=5; CHF-
Sed, n= 6; CHF-ExT, n= 4). While the bodyweight was not different among the four 
groups, the heart weight was significantly higher in CHF-Sed and CHF-ExT groups 
compared with the Sham-Sed group, suggesting cardiac hypertrophy in the CHF state. 
There was no detectable damage to the hearts of Sham mice, whereas CHF mice 
showed marked myocardial infarcts (infarct size: 33±5.4% and 30±5.5% in the Sed and 
ExT groups, respectively) (Figure 2.4A). Figure 2.4B shows the EF as a function of 
infarct size. CHF mice have different infarct sizes and therefore, different cardiac 

























































N = 6 
Sham-ExT 
N = 5 
CHF-Sed 
N = 6 
CHF-ExT 
N = 4 
Body weight, g 28.7 ± 0.4 29.4 ± 0.5 28.9 ± 0.8 
 
29.5 ± 0.7 
 
Heart weight, mg 140.3 ± 8.8 
 
149.3 ± 6.6 
 
239.9 ± 33.8* 
(p=0.016) 
 






8.3 ± 0.5 
 
9.0 ± 0.4 
 
14.3 ± 2.1* 
(p=0.017) 
 
14.8 ± 1.3 
(p=0.055) 
Wet lung weight, 
mg 
204.8 ± 4.1 
 
189.6 ± 9.9 
 
219.3 ± 8.1 
 
202.5 ± 5.2 
 
Infarct size, % of 
LV 




30.0 ± 5.5### 
(p=0.0004) 
 




N = 6 
Sham-ExT 
N = 5 
CHF-Sed 
N = 6 
CHF-ExT 
N = 4 
Body weight, g 28.7 ± 0.4 29.4 ± 0.5 28.9 ± 0.8 
 
29.5 ± 0.7 
 
Heart weight, mg 140.3 ± 8.8 
 
149.3 ± 6.6 
 
239.9 ± 33.8* 
(p=0.0167) 
 






8.3 ± 0.5 
 
9.0 ± 0.4 
 
14.3 ± 2.1* 
(p=0.0175) 
 
14.8 ± 1.3 
 
Wet lung weight, 
mg 
204.8 ± 4.1 
 
189.6 ± 9.9 
 
219.3 ± 8.1 
 
202.5 ± 5.2 
 
Infarct size, % of 
LV 




30.0 ± 5.5### 
(p=0.0004) 
 














































p  =  0 .0 0 5
H F  S e d
H F  E xT
Figure 2.4 – Heart infarcts and correlation between ejection fraction 
and infarction size 
A: Example of LV infarct (dotted line) at 12 weeks post MI 





The echocardiographic data are summarized in Table 2.3. These data are 
derived from the cohort used to measure Nrf2 in the whole brain stem (data not shown); 
Sham-Sed, n= 5; Sham-ExT, n= 6; CHF-Sed, n= 6; CHF-ExT n= 5. In this cohort, 
echocardiography was done at three-time points; before MI/Sham surgery, 4 weeks after 
surgery, and 8 weeks after exercise training (Fig. 2.5). Both CHF-Sed and CHF-ExT 
exhibited signs of impaired cardiac function. Ejection fraction and FS were significantly 
lower in CHF animals 12 weeks after myocardial infarction compared with sham animals. 
Furthermore, left ventricular volume and chamber diameter were greater in CHF animals 
compared with their respective Sham groups (Figure 2.6). The left ventricular anterior 
wall thickness was significantly lower in CHF animals; however, left ventricular posterior 
wall thickness was not altered among the four groups. Each of the four groups showed 
nearly similar EF after ExT compared with measurements before ExT, suggesting that 


































N = 5 
Sham-ExT 
N = 6 
HF-Sed 
N = 6 
HF-ExT 
N = 5 
EF, % 60.9 ± 2.3 
 
58.3 ± 2.1 23.8 ± 4.8**** 
(p<0.0001) 
29.4 ± 3.8#### 
(p<0.0001) 
FS, % 31.2 ± 3.3 
 
29.2 ± 1.9 11.2± 2.7*** 
(p=0.0002) 
14.6 ± 2.4## 
(p=0.0044) 
EDV, ul 46.8 ± 11.9 
 
63 ± 4.5 192.5 ± 34.2** 
(p=0.001) 
161 ± 23.6# 
(p=0.02) 
ESV, ul 26 ± 5.9 
 
25.2 ± 2.6 153.5 ± 30.3** 
(p=0.001) 
111.8 ± 24.3# 
(p=0.03) 
LVAW;d, mm 1.1 ± 0.1 
 
1 ± 0.1 0.5 ± 0.1** 
(p=0.002) 
0.7 ± 0.1 
 
LVAW;s, mm 1.4 ± 0.1 
 
1.5 ± 0.1 0.6 ± 0.1** 
(p=0.001) 
0.8 ± 0.1## 
p=0.005) 
LVPW;d, mm 0.9 ± 0.1 
 
1 ± 0.1 0.9 ± 0.1 1 ± 0.1 
LVPW;s, mm 1.2 ± 0.2 
 
1.2 ± 0.1 1.1 ± 0.1 1.2 ± 0.1 
LVID;d, mm 3.5 ± 0.2 
 
3.4 ± 0.4 6.1 ± 0.5** 
(p=0.001) 
5.6 ± 0.4## 
(0.006) 
LVID;s, mm 2.5 ± 0.2 
 
2.6 ± 0.1 5.5± 0.6*** 
(p=0.0004) 
5.1 ± 0.5## 
(p=0.002) 
**, ***, **** compare CHF-Sed vs sham Sed; #, ## and #### compare CHF-ExT vs sham ExT. 
EF: ejection fraction, FS: fractional shortening, EDV: end diastolic volume, ESV: end systolic volume, LVAW: 










P* < 0.05, P** < 0.01 and P*** < 0.001 vs sham Sed; P# < 0.05, P## < 0.01 and P### < 0.001 vs sham ExT 
 
















Figure 2.5 - Ejection fraction before and after MI/Sham surgery and after exercise training 
Cardiac function was evaluated by echocardiography at 3 time points: before MI or sham 
surgery, 4 wk after surgery, and after exercise training (ExT). Sham-Sed, n = 5; Sham-












Figure 2.6 - Representative M-mode, long-axis, and two-dimensional 







Hemodynamic data are shown in Table 2.4. These data are derived from two 
cohorts; the first cohort was used to measure Nrf2 in the whole brain stem (data not 
shown), the other cohort was used to measure Nrf2 and NQO-1 mRNA from the RVLM 
punches (Sham-Sed n= 5; sham-ExT n= 6; CHF-Sed n=6; CHF-ExT n= 7). The CHF-
Sed group exhibited a significantly elevated left ventricular end-diastolic pressure, and 
lower maximal and minimal dP/dt compared with the sham-Sed group. However, there 
were no significant differences in these parameters between Sham-ExT and sham-Sed 
or CHF-ExT and CHF-Sed, suggesting that ExT had no effect on cardiac function in 
health and CHF conditions. HR was not different among the groups, suggesting that the 
changes in the above cardiac parameters were not because of alteration in the HR. 























































N = 5 
Sham-ExT 
N = 6 
HF-Sed 
N = 6 
HF-ExT 
N = 7 
LVEDP, mmHg 3.4 ± 0.8 
 
2.8 ± 0.4 
 
12.5 ± 1.4* 
(p=0.018) 
11.6 ± 2.9# 
(p=0.012) 
dp/dt max, mmHg/s 9067 ± 479.1 
 
9366 ± 519.2 
 
4648 ± 679.2*** 
(p=0.0001) 
6381 ± 487.7## 
(p=0.0039) 
dp/dt min, mmHg/s -9553 ± 695.5 
 
-9983 ± 662.2 
 




Heart rate, bpm 472 ± 35.6 
 
466 ± 29.7 
 
487 ± 28.5 
 
504 ± 23.9 
 
*, ** and *** denote comparisons between CHF-Sed vs sham Sed; #, ## and ### compare CHF-ExT vs sham 






















Figure 2.8 shows an original recording for arterial baroreflex function in an acute 
anesthetized preparation. The recording clearly shows that the changes in HR response 
(bradycardia) was blunted in CHF-Sed mice and it was partially restored in CHF ExT 
mouse. Composite arterial baroreflex curves and gain curves for the control of HR in the 
4 groups of mice are shown in figure 2.9. The group data indicate a significant 
attenuation of HR range and maximal gain in CHF mice. The attenuated HR response 
and maximal were restored by ExT.  
Baroreflex parameters are quantified in figure 2.10, which shows that the HR 
range, MAP at the midpoint of HR range, bradycardia response, and the maximal gain 
were blunted in the CHF sed group. These attenuated responses were partially restored 
by ExT 
Figure 2.11 shows that despite similar increases in MAP the decrease in the HR 
the response to phenylephrine was essentially abolished in the CHF-Sed group, most 
likely indicating a dramatic reduction in vagal tone. This decrease in the HR response 
was significantly improved by ExT.  
Collectively, the baroreflex data indicate that ExT did not affect baroreflex 
sensitivity in Sham mice. The improvement in the baroreflex function after ExT was 

















 Figure 2.8 - Representative baroreflex tracing of blood pressure and heart rate. 
7 min 








Figure 2.9 - Baroreflex function and gain curves. 
Composite arterial baroreflex and gain curves of arterial baroreflex function for HR 
** denotes comparison between CHF Sed vs Sham Sed; # and ## demotes comparison between 











Figure 2.10 - Mean and individual baroreflex parameters 
A: Range 
B: MAP at midpoint of HR range 
C: minimum HR response 



































































Figure 2.11 - Change in MAP and HR after phenylephrine iv injection 
A: change in the MAP response 
B: Change in the HR response  





Exercise capacity (work performance) 
To document a training effect, mice were subjected to exercise capacity testing. 
Exercise capacity was evaluated at two-time points, 0, and 8 weeks post-ExT. These 
time points correspond to 4- and 12-weeks post MI/Sham surgery. As shown in figure 
2.12 A, Sham mice exhibited a significantly higher level of work after 8 weeks of ExT. 
While there was a trend for a higher work level in the CHF-ExT group, it did not reach 
significance. The sedentary groups of Sham and CHF mice showed either no 
improvement or a lower capacity over time. While the absolute work level after ExT was 
not different among the groups, the delta change in the work level was significantly 
higher in the exercise groups of both sham and CHF compared with their respective 






















































































Figure 2.12 - Work performance before and after exercise training 
A: Absolute work performed before and after exercise training (ExT). 





To further confirm the training adaptation at the molecular level, we measured 
CS activity in the soleus muscle (Figure 2.13). After 8 weeks of training, the CHF-ExT 
group showed a significantly higher CS activity compared with the CHF-Sed group; 
however, there was no difference between the CHF-Sed group compared with the 




























































  To further confirm the reliability of exercise testing and to rule out that 
mice were noncompliant to the testing protocol, we measured blood lactate levels 
prior and immediately following the exercise capacity test. In the resting 
condition, the blood lactate values were similar among the groups. Following the 
exercise capacity test and upon meeting exhaustion criteria, blood lactate levels 
were increased 2-3 fold in each group (figure 2.14). Both resting and maximal 
lactate levels are within the ranges published previously for resting conditions 



































































































































p<0.0001 p<0.001 p<0.0001 p<0.001




Nrf2 antibody validation 
Figure 2.15 shows the validation of the Nrf2 antibody (ab62352) using 
immunoblotting. The bands from RVLM samples observed using Nrf2 antibody were not 









Figure 2.15 - Nrf2 antibody validation by immunoblot 





Nrf2 and NQO-1 protein in the RVLM 
 In these experiments, we measured Nrf2 and one of its major target proteins 
(NQO-1), in RVLM punches. As shown in figures 2.16 and 2.17, the protein expression 
of both Nrf2 and NQO-1 was downregulated in the CHF state. ExT restored these 
proteins to near-normal levels in the CHF state. Furthermore, ExT also upregulated both 
proteins in sham mice. Nrf2 protein expression in the RVLM of mice with varying 


























Figure 2.16 - Nrf2 protein expression in the RVLM punches 








































































Figure 2.17 - NQO-1protein expression in RVLM punches 







Nrf2 and NQO-1 mRNA in the RVLM 
 
To evaluate the mechanism by which ExT increases Nrf2 and NQO-1 proteins, 
we measured their mRNA levels in the RVLM. Similar to protein data, the mRNA levels 
of both Nrf2 and NQO-1 were significantly lower in the RVLM of mice with CHF. ExT 
prevented downregulation of both proteins in the CHF state and upregulated both 
proteins in the sham group (figure 2.19). Nrf2 mRNA in the RVLM of mice with varying 










Figure 2.18 - Correlation between Nrf2 protein expression in the RVLM and EF 









































































































Nrf2  in visual cerebral cortex 
 
We also evaluated the effect of ExT on Nrf2 expression in the visual cerebral 
cortex, an area that does not include, to the best of our knowledge, autonomic 
neurons. As shown in figure 2.21, ExT did not alter Nrf2 mRNA and protein 























































































Urinary and plasma NE 
 
As an indirect index of sympathetic nerve activity in conscious mice, urinary NE 
excretion was measured 12 weeks following MI and after three days of acclimatization to 
a metabolic cage. As shown in Figure 2.22, urinary NE concentration was significantly 
higher in the CHF-Sed group compared with Sham Sed. ExT prevented the increase in 
NE concentration. However, the urinary NE concentration may not necessarily reflect 
sympathetic nerve activity, as such, we measured urinary NE excretion. The amount of 
urinary volume in 24 hours was not different among groups and the increase in NE 
excretion rate in CHF was prevented by Ext. 
To further validate the beneficial effect of ExT on the sympathetic outflow, we 
measured plasma NE. CHF-Sed mice had significantly higher plasma NE concentration. 
ExT, although not statistically significant (p=0.07), prevented the increase in the plasma 






















































































Figure 2.22 - Urinary NE levels 
24 h urine volume (A), Urinary NE concentration (B), and urinary NE 




























































In the present study, we tested the hypothesis that ExT increases Nrf2 and NQO-
1 expression in the RVLM of mice with CHF subjected to a moderate intensity ExT 
regimen. This study demonstrates that Nrf2 and NQO-1 are downregulated in the RVLM 
of mice with CHF, which was accompanied by elevated urinary NE excretion. ExT 
normalized the expression of both Nrf2 and NQO-1, as well as urinary NE excretion. 
These findings suggest that ExT in CHF activates a central Nrf2 antioxidant signaling 
pathway and upregulates antioxidant enzymes to regulate redox balance and 
sympathetic outflow.  
Exercise training only slightly improved the increased LVEDP and the decreased 
maximal rate of pressure change (dP/dtmax). ExT did not improve the decreased EF 
associated with CHF. The fact that ExT did not increase cardiac function in mice with 
CHF should not be unexpected. The beneficial effects of ExT in patients with CHF may 
be primarily due to improvement in neurohumoral drive and therefore the cardiovascular 
regulation and fluid balance [307] and peripheral blood flow. ExT also failed to improve 
cardiac function of sham mice in this study. The reason for this is not clear, however it is 
possible that the level of exercise training was not high enough to show changes in 
young healthy mice. Alternatively, it is possible that anesthesia masks the improvement 
in cardiac function as assessed by echocardiography in this group of mice. The present 
study also supports the hypothesis that ExT enhances arterial baroreflex function in the 
CHF state, which is in agreement with our lab’s previous findings in rats [308] and 
rabbits [133] with CHF. Previous findings from our and other laboratories suggest that 
ExT improves sympatho-vagal balance. For instance, our lab has previously shown that 
ExT increases HR range and baroreflex gain in the unblocked state and after 
sympathetic blockade with metoprolol, but not after parasympathetic blockade with 
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atropine [309], indicating that augmented vagal tone to the sinoatrial node enhances 
baroreflex control of HR.  
Another mechanism that may also be relevant in explaining the baroreflex results 
in this study is Ang II and oxidative stress. ExT has been shown to prevent the decrease 
in baroreflex sensitivity in response to intracerebroventricular infusion of Ang II, which 
was associated with downregulation of AT1R and NOx2 subunit protein expression in 
the PVN [308]. Furthermore, enhanced baroreflex sensitivity after ExT is associated with 
upregulation of antioxidant enzymes and reduced O2•–  production in the RVLM of rabbits 
with CHF [133].  
Citrate synthase is a pace-making enzyme in the Krebs cycle. As such, it is 
considered a reliable indicator of cellular aerobic metabolism [310]. After ExT, CHF-ExT 
mice exhibited significantly higher activity of CS compared with CHF-Sed mice; however, 
CS activity was not different at baseline in CHF-Sed compared with Sham-Sed. Despite 
the fact that CHF has been characterized with skeletal myopathy [189] (usually an 
advanced symptom), we did not observe a reduction in body weight or soleus weight 
(data not shown) in CHF mice. Reduction of CS activity in skeletal muscle may suggest 
that de novo ATP synthase during exercise is impaired, therefore, increased CS activity 
in Sham-ExT (p=0.05) and CHF-ExT (p=0.006) suggest that aerobic metabolism is 
improved in both trained groups. Overall, these data show a significant training effect in 
both Sham and CHF mice. 
Blood lactate provides a biochemical indicator of exercise-induced exhaustion at 
or near VO2max [302, 303]. The rise in the blood lactate during the exercise 
performance test indicates that the mice meeting the exhaustion criteria were fatigued 
and not incompliant with the exercise capacity protocol.  
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The RVLM is a major brain stem nucleus and considered to be a common 
projection pathway of pre-sympathetic neurons descending to the spinal cord to regulate 
sympathetic outflow and cardiovascular function [100, 311]. In addition, the RVLM 
receives inhibitory projections from the caudal ventrolateral medulla, which modulates 
arterial baroreflex regulation of sympathetic nerve activity, HR, and peripheral resistance 
[312]. We have previously shown that selective deletion of the Nrf2 gene in the RVLM of 
normal Nrf2 floxed mice leads to an increase in RVLM ROS levels concomitant with 
downregulation of antioxidant enzymes [132]. Importantly, these mice exhibited 
significant elevation of blood pressure, urinary NE and renal sympathetic nerve activity. 
Conversely, ou lab laboratory has also recently shown that overexpression of Nrf2 in the 
RVLM of mice with CHF reduced sympathetic outflow along with a reduction in ROS and 
an increase in several Nrf2-dependent antioxidant enzymes [294]. These data strongly 
suggest that in the RVLM, Nrf2 contributes to alterations in ROS, blood pressure and 
sympatho-excitation. The present data showing downregulation of Nrf2 in the RVLM of 
CHF mice suggests that decreased antioxidant enzymes and sympatho-excitation in 
CHF may be mediated, in part, by impaired Nrf2 signaling in the RVLM. This is 
consistent with previous data in the heart, where Nrf2  appears to also be downregulated 
in CHF [248] and may contribute to the cardiac remodeling process [313]. However, no 
studies have examined the effects of ExT on cardiac Nrf2 expression in the CHF state.  
The results of this study further support increasing evidence that antioxidant 
enzymes such as NQO-1 are decreased in sympatho-regulatory areas of the brain in 
CHF [113, 133]. In addition, these data clearly show that ExT upregulates Nrf2 and 
NQO-1 mRNA and protein expression in the RVLM of mice with CHF. Exercise may 
provide a stimulus for upregulation of antioxidant enzymes in regions remote from the 
exercising muscle. In addition, these data are consistent with previous reports that 
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demonstrate upregulation of antioxidant enzymes in the brain, and other regions in 
response to ExT [133, 314, 315]. However, the precise mechanism that converts ExT 
into changes in antioxidant enzymes is not known. One possibility, for which there is a 
growing body of literature, is the idea that extracellular vesicles shed from exercising 
skeletal muscle can influence remote tissues, including the brain, by transferring their 
cargo and regulating oxidative stress [316]. Indeed, in a recent study from our laboratory 
[248] we clearly showed that exosomes released from cardiac myocytes contain 
microRNAs that are specific to the translation of Nrf2. 
In a review by Finkel and Holbrook [317], they propose that the best strategy to 
increase antioxidant defense mechanisms may be to periodically increase sub-lethal 
oxidative stress. Therefore, it is possible that some of the beneficial effects of ExT are 
derived from such a stress-tolerance mechanism. One of the major benefits associated 
with non-exhaustive ExT is the induction of mild oxidative stress that stimulates the 
expression of antioxidant enzymes integral to several redox signaling pathways [318]. 
During ExT, skeletal muscle generates large amounts of ROS [319, 320] that, in part 
through lipid peroxidation, may provide a stimulus for other tissues, including the RVLM. 
Such a mechanism may condition pre-sympathetic neurons to cope with oxidative 
stress. Presumably, this adaptation occurs because of cumulative effects of repeated 
bouts of exercise on gene expression of antioxidant enzymes. The intracellular 
mechanisms triggered by ExT to upregulate antioxidant enzymes are still unclear. One 
possible mechanism is that exercise-associated increase in metabolic activity, probably 
from mitochondria, of pre-sympathetic neurons[321] triggers ROS production, which in 
turn, activates Nrf2. 
There are several redox-sensitive transcription factors such as NF-kB and Nrf2 
[252, 322, 323], that may be involved in the transduction mechanism by which ExT alters 
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protein transcription in the brain. ExT has been shown to modulate both of these 
proteins [324-326]. Previous data from the literature show that the pro-oxidant NF-kB 
and antioxidant Nrf2 transcription factors compete for binding to the nuclear creb binding 
protein [252]; as such, both transcription factors are critical for regulating intracellular 
oxidative stress. This lab has previously shown that ExT decreased NF-kB signaling in 
the brain of rabbits with CHF [133]. Although there are no studies showing this 
competition in the RVLM, we speculate that in CHF, NF-kB reduces the ability of Nrf2 to 
bind to the CBP, which further reduces its ability to stimulate downstream antioxidant 
response elements and thus antioxidant enzymes. Data in the present study showing 
upregulation of Nrf2 in the RVLM may indicate that the ExT-induced upregulation of 
antioxidant enzymes is mediated, in part, by Nrf2 through restoration of the balance 
between Nrf2 and NF-kB.  
While the findings in this study showed an association between Nrf2 and NQO-1 
in response to ExT in the CHF state, it is not completely clear if the change in the 
expression of NQO-1 is mediated by Nrf2. Furthermore, we cannot determine whether 
ExT-induced reduction of urinary NE excretion in CHF mice is Nrf2 dependent. To 
determine whether ExT decreases sympathetic nerve activity and upregulates 
antioxidant enzymes in the RVLM by a Nrf2-dependent mechanism in CHF, future 
experiments on Nrf2-floxed mice treated with RVLM Cre virus will have to be carried out. 
However, as indicated above [294], when Nrf2 was overexpressed in the RVLM 
following the delivery of Cre virus to Keap1 floxed mice with CHF, marked sympatho-




Limitations and perspectives of the current study 
One potential limitation in this study is the lack of evaluation of oxidative stress in 
the RVLM. Our lab has published several papers showing that up and downregulation of 
Nrf2 in the RVLM of both normal and CHF mice results in an inverse relationship 
between oxidative stress and Nrf2 expression [294, 299, 308]. The fact that ExT reduces 
oxidative stress is not new; a more important question is to determine whether the 
reduction of oxidative stress in the RVLM after the ExT regimen in the CHF state is Nrf2- 
dependent.  
ExT in the CHF state is currently an area of intense investigation. While many 
studies [327, 328] have shown that ExT is beneficial in CHF, the mechanism by which 
this occurs is largely unknown. This study revealed a new potential mechanism through 
which ExT upregulates antioxidant enzymes and decreases sympathetic nerve activity in 
CHF. The data provided here suggest that ExT in CHF provides a stimulus for a central 
mechanism through which antioxidant enzymes are normalized, most likely due to a 
change in Nrf2 expression. These studies further suggest that reduction in sympathetic 
nerve activity in the CHF state can be mediated through ExT or activation of the Nrf2 
pathway with precisely targeted small molecule activators of Nrf2. Figure 2.24 shows an 


































Figure 2.24 - Summery and overview of the present study 
A schematic of the nuclear factor erythroid 2-related factor 2 (Nrf2)/Keap1 signaling pathway 
and some of the potential mechanisms by which exercise training (ExT) may impact Nrf2, 
























CHAPTER III: CURCUMIN IMPROVES EXERCISE 
PERFORMANCE OF MICE WITH CHRONIC HEART 























Chronic heart failure is an extensive health care problem with premature death 
and repeated hospitalizations. However, the burden of CHF extends beyond mortality as 
it profoundly impacts the quality of life. One of the cardinal symptoms of CHF that 
jeopardize independency and worsening prognosis is exercise intolerance [329, 330] 
Given that CHF is characterized by left ventricular dysfunction, it was historically 
presumed that the severity of cardiac dysfunction is related to the degree of intolerance 
in CHF patients [330]. Subsequent studies [331, 332] showed that reduced blood flow to 
skeletal muscle resulted in limited exercise capacity during incremental exercise testing. 
Thus, it was presumed that the reduced cardiac output during exercise results in under 
perfusion of the exercising skeletal musculature, which leads to earlier onset of 
intramuscular acidosis and subsequently induced fatigue and exhaustion [333]. 
However, several studies showed that even after improving skeletal muscle blood flow, 
exercise capacity was not improved [173, 175, 331]. Consequently, it has been 
proposed that other peripheral factors, particularly skeletal muscle abnormalities, may 
represent a common underlying etiology of exercise intolerance.  
The significance of skeletal muscle abnormalities in CHF is that functional and 
structural abnormalities are correlated with the severity of CHF [190, 193], and more 
importantly with the degree of exercise intolerance. For instance, muscle mass [334], 
muscle strength [335], the number of capillaries per fiber [336, 337], and ex vivo skeletal 
muscle oxidative capacity [338] show a strong relationship with maximal and/or 
submaximal exercise capacity. At the muscle fiber level, lower VO2max is associated 
with a greater percentage of fast-twitch muscle fibers [336, 339], which have a lower 
fatigue resistance. Skeletal muscle dysfunction (skeletal myopathy) is caused, in part, by 
105 
 
increased ROS and/or decreased antioxidant enzymes in skeletal muscle during CHF 
state. For instance, it has been demonstrated that, in the skeletal muscles of CHF 
patients and animals, SODs, catalase, glutathione peroxidase, and other antioxidant 
enzymes were significantly downregulated [340-342]. Skeletal muscle-specific 
overexpression of SOD3 by somatic gene transfer in CHF mice significantly attenuated 
muscle atrophy and dysfunction. In addition, the upregulation of antioxidant enzymes in 
skeletal muscles is a principle mechanism underlying the improved exercise capacity 
following exercise training in both CHF patients [340, 343] and animals [344, 345]. 
However, the underlying mechanism for endogenous downregulation of antioxidant 
enzymes in the skeletal muscle in the CHF state is not clear. Given the evidence for the 
important role of Nrf2 in antioxidant defense, we sought to establish the link between 
CHF-induced exercise intolerance, alterations in antioxidant enzymes regulation, and 
Nrf2. Using an integrated physiological approach, our results suggest that in skeletal 
muscle, reduced Nrf2 signaling contributes to the impaired antioxidant expression, which 
is associated with reduced exercise capacity. Here we chose to determine if 
pharmacological activation of Nrf2 by curcumin increases the expression of 
















Forty male C57BL/6 mice 10 weeks of age were used, which were assigned to four 
groups: Sham-Vehicle (Sham-Veh, n = 8), Sham-Curcumin (Sham-Cur, n = 9), CHF-
Vehicle (CHF-Veh, n = 12), CHF-Curcumin (CHF-Cur, n = 11). 
Induction of heart failure  
CHF was produced by left coronary artery ligation as described in Chapter II with 
modifications for this study. Although exercise intolerance is a common symptom in CHF 
patients, skeletal myopathy and sarcopenia usually emerge at an advanced stage of the 
disease (e.g., NYHA Class IV) [206]. Therefore, we aimed to generate CHF mice with a 
large myocardial infarction (>70%) and markedly low EF (<25%). Briefly, while under 
isoflurane anesthesia (~2%, 98% O2), mice were intubated and ventilated by a mouse 
ventilator (tidal volume: 150−250 μl; frequency: 200 breaths/min; Mouse Ventilator 
MiniVent, model no. 845; Hugo Sachs Elektronik, March-Hugstetten, Germany). The 
hearts were exposed through a left thoracotomy by an incision in the fourth left 
intercostal space. Instead of ligating the anterior descending branch of the left coronary 
artery, a permanent ligation was made with 7.0 suture as high as possible near the aorta 
to produce a large myocardial infarction. Sham mice underwent thoracotomy and 
manipulation of the heart, but no coronary artery ligation was performed. This modified 
method generated very severe CHF mice compared with those in our study in chapter II. 
To improve the survival rate, the mice were placed in a recovery cage for three days 
after surgery. A regular Micro-Isolator mouse cage (16 × 30 cm with a micro-isolator cap) 
was placed on a 30–32°C heating pad and received a continuous delivery of 100% 




Echocardiograms were carried out on all mice at four weeks post-MI or sham 
surgery as described in chapter II. 
Curcumin administration 
 Curcumin (Cur, 50 mg/kg/day) was continuously supplied with two osmotic 
minipumps (AP1004, Alzet). The first pump was implanted subcutaneously in the 
midscapular area at 12 weeks post-MI surgery and replaced with a new pump after 4 
weeks corresponding to the useful capacity of the pump. The total duration of Cur 
treatment was 8 weeks. 
In vivo Experiments 
 
Maximal Exercise Capacity Testing  
 Exercise capacity was tested on a mouse treadmill as described in chapter II. 
 
Whole-body tension 
 Whole-body tension was used to evaluate muscle contractility in vivo, as 
previously described [346]. Briefly, mice were placed in a solid polyvinyl chloride (PVC) 
tube, which is 1-foot length, 1.5-inch diameter and lined with aluminum mesh from the 
interior (figure 3.1). The tail of the mouse was attached to a force transducer by #1 
suture, which was 5-7 cm in length. The force exerted on the transducer was recorded 
by a Powerlab (ADInstruments, Inc. Colorado Springs, CO) system. In order to motivate 
the mouse to move forward, the tail was stroked with a serrated forceps and the forward 
pulling tension was measured. Each mouse received 10-13 strokes in 50 seconds with 
about 2-4 seconds intervals between strokes. The mean value of the 5 peak readings 
















Figure 3.1 - Schematic showing whole body tension measurement 
The figure shows the mouse position inside a Plexiglass tube with the tail 




In situ Muscle Contractility  
Functional assessment of in situ Sol and EDL muscle performance was carried 
out based on a modified method used for the tibialis anterior muscle [347, 348]. Figure 
3.2 demonstrates in situ assessment of muscle contractility. Briefly, under ~2% 
isoflurane anesthesia, mice were placed on a metal heating pad in the prone position. A 
small incision on the skin above the calf was made and the Sol and EDL were identified. 
The proximal tendon of the Sol and the distal tendon of the EDL were isolated, cut and 
sutured with a #6 silk suture, by which the tendon was attached to a force transducer 
(MLT1030/A, ADInstruments, Inc. Colorado Springs, CO). The muscle belly was 
carefully kept intact with normal vasculature and innervation. A silver bipolar electrode 
was inserted into the muscle belly and an intermittent tetanic stimulation with trains of 
square wave pulses (2.5V, 0.3s at 50Hz per 3 sec for a total of 20 min) was delivered by 
a pulse generator (A310, WPI, Inc. Sarasota, FL). During the experiment, the mice were 
kept warm by an isothermal pad and heat lamp while the muscles and tendons were 






























Stimulation (20 min) 
 
Figure 3.2 – Schematic of In vivo muscle contractile force measurement. 
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Ex Vivo Experiments 
Immunohistochemistry 
 Muscle fiber types and morphology were examined by immunofluorescence 
staining to detect myosin heavy chain (MHC) expression as previously described [349]. 
In brief, after sacrifice, the Sol and EDL were harvested, embedded in O.C.T. compound 
side by side, and cut into 10 um thick cryosections with a cryostat (Leica CM1850, 
Germany) maintained at -20C. The sections of the mid-belly were used for 
immunofluorescence staining. First, the sections were blocked with 10% goat serum in 
PBS for 60 min, followed by 60 min incubation with a primary antibody cocktail (BA-F8 to 
MHCI (1:50), SC-71 to MHCIIa (1:600), and BF-F3 to MHCIIb (1:100); Developmental 
Studies Hybridoma Bank, University of Iowa).  After washing 3 times with PBS, the 
sections were incubated 60 min with a secondary antibody cocktail (Alexa Fluor 350 
IgG2b (1:500), Alexa Fluor 555 IgG1 (1:500), and Alexa Fluor 488 M (1:500); Invitrogen), 
followed by 3 times PBS wash. The slices were then mounted with an Aqua-Mount 
mounting medium (VWR, Radno, PA), and then were examined with a laser confocal 
microscope (Leica TSC STED). Cross-sectional area (CSA) was determined for each 
fiber separately using ImageJ software, based on the publication by Papadopulos, et 
al.[350]. Eight slices per muscle were assessed to obtain an average CSA for each type 
of myofiber/muscle/mouse, which was then used for statistical analysis. The minimal 







Western blot analyses 
         The skeletal muscle tissues were homogenized in RIPA buffer (50 mM TrisHCl 
pH7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.1% SDS), from which total protein was 
extracted by centrifuging at 20000 g. The protein concentration of the extract was 
measured using a protein assay kit (Pierce; Rockford, IL) and then adjusted to equal 
volume in all samples with 2X 4% SDS sample buffer. The samples were boiled for 5 
min and then loaded on a 7.5% SDS-PAGE gel (30 ug protein/10 ul per well) following 
by electrophoresis using a Bio-Rad mini gel apparatus at 40 mA/gel for 45 min. The 
fractionalized protein on the gel was electrically transferred onto a polyvinyl difluoride 
membrane (Millipore). The membrane was first probed with the primary antibodies (Nrf2 
ab-137550, Keap1 sc-33569, HO-1 ab-68477, NQO1 ab-80588, SOD2 sc-30080, 
Catalase sc-50508, gp 91 BD-611414, ubiquitinated proteins BML-PW0930, Myogenin 
sc-576, and MyoD sc-760; from Abcam, Santa Cruz Biotechnology, BD Biosciences, and 
Enzo Life Sciences) and then the secondary antibody (HRP Goat Anti-Rabbit IgG 
Antibody and HRP Goat anti-Mouse IgG, HRP, Thermo-Fisher Scientific). After 3 times 
washing with TBST, the membrane was treated with enhanced chemiluminescence 
substrate (Pierce; Rockford, IL) for 5 min. The blots on the membrane were visualized 
and analyzed using a UVP BioImaging System. The membranes were then treated with 
Restore Western Blot Stripping Buffer (Thermo Scientific) to remove the blots, followed 
by probing with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primary 
antibodies (sc-32233) or a-Tubulin (ab-64332) to get GAPDH/a-Tubulin blots as the 
internal control. The final reported data are the normalized target protein band densities 





Statistical analysis   
 All of the data are expressed as mean ± SE. A 2-way repeated-measures 
ANOVA with the Student-Newman-Keuls test was used for analyzing the differences 





















Morphological and echocardiographic data  
 Table 3.1 summarizes morphological and echocardiographic measurements in 
the four groups. The CHF-Veh group exhibited significantly increased heart weight, 
decreased EF and FS. However, there were no differences in these parameters between 
Sham-Veh and Sham-Cur or CHF-Veh and CHF-Cur, suggesting that Cur had no effects 
on cardiac function in healthy and failing hearts. 
 Figure 3.3 shows the representative gross anatomy, heart weight, 
echocardiograms, and ejection fraction from Sham and CHF mice. Compared with the 
Sham hearts, the failing hearts were markedly dilated, with a ~2 fold increase in the 
weight and size. The free wall of the left ventricle was almost entirely replaced by scar 
tissue with an infarct size of about 80% of the LV free wall. The right ventricle and atria 
were significantly enlarged and hypertrophied, a typical pathological finding in advanced 
heart failure. Correspondingly, these hearts displayed significantly impaired function (EF: 






































N = 8 
Sham-Cur 
N = 9 
CHF-Veh 
N = 12 
CHF-Cur 
N = 11 
Heart weight, mg 140 ± 0.01 140 ± 0.01 260 ± 0.04**  280 ± 0.06## 
 
 
Atria weight, mg 15.0 ± 1.0 15.5 ± 0.7 43.1 ± 3.4** 46.8 ± 2.6## 
Right ventricle, mg 26.95 ± 2.6 27.85 ± 2.2 64.8** ± 6.1 69.3 ± 7.3## 
Infarct size, % of 
LV 






68.6 ± 8.4 67.3 ± 7.9 21.3 ± 2.1** 19.5 ± 3.3## 
 Fractional 
shortening, % 
34.8 ± 5.5 36.1 ± 4.8 10.1 ± 2.1** 11.3 ± 1.8## 
* and **** compare CHF-Veh vs sham-Veh; ## and ####  compare CHF-Cur vs sham-Cur 
* and **** compare CHF-Veh vs sham-Veh; ## and ####  compare CHF-Cur vs sham-Cur 




















Veh Cur Veh Cur 
Figure 3.3 - Representative hearts and echocardiograms. 
Representative hearts and echocardiograms for sham-vehicle (Sh-Veh; top, left), sham-curcumin (Sh-
Cur; top, right), heart failure-vehicle (HF-Veh; bottom, left), and heart failure-curcumin (HF-Cur; bottom, 
right) group. Dotted lines outline the infarct areas where the myocardium is replaced by scars. Numbers 
in the bottom are not the mean data. 
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Hemodynamic data  
 Table 3.2 summarizes hemodynamic measurements in the four groups. The 
CHF-Veh group exhibited significantly elevated left ventricular end-diastolic pressure 
and reduced maximal and minimal dp/dt, compared with the Sham-Veh group. However, 
there were no differences in these parameters between Sham-Veh and Sham-Cur or 
CHF-Veh and CHF-Cur, suggesting that Cur had no effects on cardiac function in 
healthy and failing hearts. Figure 3.4 shows representative hemodynamics tracing from 











N = 8 
Sham-Cur 
N = 9 
CHF-Veh 
N = 12 
CHF-Cur 
N = 11 
LVEDP, mmHg 1.3 ± 1.4 
 
0.9 ± 2.1 
 
29.8 ± 7.8** 27.4 ± 6.3## 
 
dp/dt max, mmHg/s 12138 ± 919 
 
11198 ± 1001 
 
2101 ± 315***  
(p=0.0001) 
2198 ± 333### 
(p=0.0039) 
dp/dt min, mmHg/s -12952 ± 867 
 
-12166 ± 981 
 




** and *** denote comparisons between CHF-Veh vs sham-Veh;  ## and ### compare CHF-Cur 
vs sham-Cur 
LVEDP: left ventricular end diastolic pressure  
** and *** denote comparisons between CHF-Veh vs sham-Veh;  ## and ### compare CHF-Cur 
vs sham-Cur 
LVEDP: left ventricular end diastolic pressure  
 



















Exercise capacity and whole-body tension 
 Exercise capacity was evaluated on a treadmill at three-time points, 0 (pre-), 4, 
and 8 weeks post Cur treatments, correspondingly at 12, 16, and 20 weeks post-MI or at 
the ages of 22, 26, and 30 weeks of age.  
 CHF-Veh mice displayed a significantly reduced running distance and slower 
speed compared with Sham-Veh mice in all tests, validating exercise intolerance (Figure 
3.5A). Sham-Cur mice exhibited an increase in maximum running distance and speed at 
8 weeks compared with the baseline (at 0 week), and Sham-Veh at eight weeks, 
suggesting that Cur enhanced exercise capacity in the healthy state. On the other hand, 
distance and speed at eight weeks were decreased in CHF-Veh, but there was no 
significant change in the CHF-Cur group as compared with the baseline at zero weeks. 
Although no difference was observed between zero and eight weeks, the CHF-Cur 
group exhibited significantly better exercise performance (distance and speed) at eight 
weeks as compared with the CHF-Veh group, suggesting that Cur prevented the decline 
in running performance in HF. During this period, no difference in body weight was found 
among these groups. Figure 3.5B shows whole-body tension at eight weeks post Cur 
treatment. CHF-Veh displayed a significantly lower whole-body pulling force than Sham-












Figure 3.5 - Exercise performance and whole-body tension 
Exercise performance [top: body weight (BW); middle: Max Dis, maximum distance; bottom: Max 
Sp, maximum speed; Cur: weeks postcurcumin treatment; MI (myocardial infarction) weeks post-
MI surgery]. B: whole-limb grip force generation (top: original recording; bottom: mean data). 
Groups are sham-vehicle (Sh-Veh, n = 8), sham-curcumin (Sh-Cur, n = 9), heart failure-vehicle (HF-
Veh, n = 12), and HF-curcumin (HF-Cur, n = 11). **P < 0.01 HF-Veh vs. Sh-Veh; @P < 0.05 HF-Cur vs. 




In situ muscle contractility 
 Sol and EDL muscles were selected for determination of muscle contractility in 
situ because they represent typical oxidative (FI and FIIa in Sol) and glycolytic (FIIb in 
EDL) muscles, respectively. Figure 3.6, Panel A is a representative time course profile of 
maximal contractility during tetanic stimulation. Panel B shows representative traces of 
force and force generation rate at the 1st and 400th tetanic stimuli. Panel C shows the 
mean data. In Sham-Veh mice, the force developed by the Sol was maintained during 
the entire period of stimulation, whereas the force of the EDL rapidly declined with time, 
confirming the fatigue resistance of oxidative muscles (Sol) and fatigability of glycolytic 
muscles (EDL). Curcumin had no effects on this parameter in Sham mice (Sham-Cur). 
The Sol of the CHF-Veh mice displayed a similar force during the first several stimuli, but 
significantly decreased with time, as compared with the Sol of the Sham-Veh. The EDL 
of the CHF-Veh mice exhibited a significantly lower force in both initial and latter tetanic 
stimuli compared to the EDL of Sham-Veh, suggesting dysfunction of Sol and EDL in 

























Figure 3.6 – In situ Sol and EDL contractility 
 In situ soleus (Sol) and extensor digitorum longus (EDL) force. A: representative time course 
profiles of maximal contractile response. B: representative tracings of force (red) and force 
generation rate (blue) of first and last tetanus. Light green horizontal trace is the stimuli markers 
(300 ms, 50 Hz). C: mean data of force generation of the first and last tetanus. Groups are sham-
vehicle (Sh-Veh, n = 8), sham-curcumin (Sh-Cur, n = 9), heart failure-vehicle (HF-Veh, n = 12), and 
HF-curcumin (HF-Cur, n = 11). *P < 0.05 compared with first of Sh-Veh @P < 0.05 compared with 
first of HF-Veh; #P < 0.05 compared with 400th of Sh-Veh; $P < 0.05 compared with 400th of HF-
Veh; %P < 0.05 compared with first of Sh-Veh and Sh-Cur. 
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Immunofluorescence assessment of fiber type 
 Figure 3.7 shows that soleus and EDL have different fiber types and distribution. 
Panel A shows that the Sol contained almost equal numbers of type I and IIa fibers, both 
of which are oxidative fibers, whereas EDL was composed primarily of glycolytic type IIb 
fibers. Type IIa fibers in the EDL were smaller in size compared with the IIa fibers in the 
Sol. These differences in fiber composition form the well-characterized basis of 
functional characteristics in Sol and EDL. Panel B of figure 3.7 shows muscle fiber 
composition and size for each group. CHF-Veh mice exhibited a significant increase in 
type IIa fibers and decreased type I in the Sol and decreased IIb fibers in the EDL as 
compared with Sham-Veh. In addition, fiber CSA was significantly reduced in both Sol 
and EDL of CHF-Veh as compared with Sham-Veh. These morphologic alterations in 
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Figure 3.7 - Immunofluorescence staining of Soleus  and EDL 
Immunofluorescence staining assessment of fiber type and size in situ soleus (Sol) and extensor 
digitorum longus (EDL) muscles. A: distribution of type I fibers (blue), IIa (red), and IIb (green) in 
Sol and EDL of a normal mouse. Bar represents 100 μm. Representative images (B), fiber 
composition (C), and fiber size (D) of Sol and EDL in the four groups of mice. Fiber-type specific 
cross-sectional areas (CSAs) in a given muscle of individual animal were provided by averaging 
CSAs of fibers in Sol/EDL with the numbers of FI in 208–264/24–96, FIIa in 224–560/136–392, 
and FIIb in 32–64/616–872. Groups are sham-vehicle (Sh-Veh, n = 8), sham-curcumin (Sh-Cur, n 
= 9), heart failure-vehicle (HF-Veh, n = 12), and HF-curcumin (HF-Cur, n = 11). *P < 0.05 vs. Sh-
Veh; @P < 0.05 vs. HF-Veh. 
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Nrf2 and Nrf2-targeted proteins expression in Sol and EDL 
 Figure 3.8 shows the expression of Nrf2 and its target proteins in both muscles. 
Sol and EDL exhibited differential expression profiles; Nrf2, HO-1, and GAPDH were 
highly expressed in EDL, whereas SOD2 and Catalase were largely expressed in Sol. 
This finding suggests a different redox status and metabolic characteristic of oxidative 
and glycolytic muscles. There was no difference in the levels of Keap1, gp91, and α-
tubulin between these two muscle types. Compared with Sham-Veh, CHF-Veh displayed 
lower Nrf2, HO-1, and SOD2 in both Sol and EDL, which were restored by Cur, 
suggesting an impaired antioxidant defense in CHF and a potential beneficial effect of 
Nrf2 activation on muscle antioxidant capacity. In addition, Cur upregulated Nrf2, HO-1, 
and SOD2 expression in Sham mice, suggesting that Cur enhances the antioxidant 
defenses even in healthy muscle. However, Cur did not affect Keap1, GAPDH, or α-


























Figure 3.8 - Nrf2 and its target proteins expression in Sol and EDL 
Western blots show the expression of Nrf2 and associated proteins in soleus (Sol) and extensor 
digitorum longus (EDL) of sham and heart failure with low ejection fraction (HFrEF) mice. 
Downregulated nuclear factor E2-related factor 2 (Nrf2) and target proteins in muscles of HFrEF 
mice were attenuated by curcumin. Cat, catalase; Keap1, Kelch-like ECH associated protein 1; HO-
1 hemeoxygenase; gp91, glycosylated 91-kDa glycoprotein component of flavocytochrome b558. 
Groups are sham-vehicle (Sh-Veh, n = 8), sham-curcumin (Sh-Cur, n = 9), heart failure-vehicle (HF-
Veh, n = 12), and HF-curcumin (HF-Cur, n = 11). *P < 0.05 and **P < 0.01 vs. Sh; #P < 0.05 and ##P 





Ubiquitinated proteins, myogenin, and MyoD expression in Sol and EDL 
 Figure 3.9 shows expression of muscle proteins related to atrophy. In both 
Soleus and EDL of CHF mice, total ubiquitinated proteins were significantly elevated, 
suggesting an abnormal increased in the activity of UPS system. To further support this 
conclusion, we measured MuRF1 and atrogen-1, two muscle-specific E3 ubiquitin ligase. 
MuRF-1 is highly expressed in soleus whereas Atrogen-1 is highly expressed in EDL, 
implying different mechanisms for protein degradation in oxidative and glycolytic 
muscles. While Cur reduced Atrogen-1 in both sham and CHF, Atrogen-1 was not 
increased in CHF compared with sham group. MuRF1 was significantly increased in 
CHF in both soleus and EDL. Cur treatment prevented the increase in MuRF-1 in both 
muscle in CHF state. Myogenin and MyoD are myogenic regulatory factors (transcription 
factors) that regulate moyoblast differentiation into myofibers [351]. Both transcription 
factors were significantly downregulated in soleus and EDL of CHF. Cur treatment 




















Figure 3.9 - Ubiquitinated, Myogenin, and MyoD expression in Soleus and EDL 
Expression of ubiquitinated-proteins, myogenin, and MyoD. Groups are sham-vehicle 
(Sh-Veh, n = 8), sham-curcumin (Sh-Cur, n = 9), heart failure-vehicle (HF-Veh, n = 12), 





Exercise intolerance is a major clinical manifestation in CHF that not only worsens 
prognosis, but also profoundly affects patients' quality of life [333, 352]. Ample evidence 
indicates that exercise intolerance in CHF is not necessarily directly related to the 
degree of cardiac dysfunction; instead it is, in part, directly related to skeletal muscle 
abnormalities such atrophy, shift from type I to type II fibers, metabolic dysfunction, 
impaired excitation-contraction coupling, and decreased muscle contractility [190, 290, 
353]. While these pathological alterations in skeletal muscle play a critical role in CHF 
symptoms such as exercise intolerance, the underlying mechanism remains to be 
elucidated and pharmacological therapies are unavailable. In this study, we evaluated 
therapeutic potential of antioxidant intervention on exercise intolerance in mice with 
CHF. We found that CHF mice displayed markedly impaired exercise performance and 
whole-body pulling force, impaired muscle contractility, and reduced fatigue-resistant 
type I fiber number and size. Furthermore, we demonstrated that in CHF mice, Nrf2, 
antioxidant enzymes, Myogenin, and MyoD were significantly downregulated, whereas 
ubiquitinated proteins were increased. These functional impairments and morphological 
abnormalities were attenuated by the chronic administration of Cur. These data suggest 
that impaired Nrf2 signaling and antioxidant defenses contribute to skeletal myopathy 
and that pharmacological activation of Nrf2 by Cur is a promising therapeutic strategy to 
improve exercise capacity in the setting of chronic CHF. However, we did not evaluate 
the oxidative status per se in animals and tissues in the present study, thus limiting our 
conclusions concerning the role of and specificity of the ROS that may be involved.  
Repetitive muscle contractions leads to a dramatic increase in the production of 
ROS due to the high oxygen consumption in mitochondria and enhanced activity of the 
electron transport chain. During aerobic exercise, skeletal muscles produce 50-100 fold 
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more ROS as compared with the resting condition [354, 355], including O2 ,̄ H2O2, and -
OH [356-359]. These unstable molecules and ions are extremely reactive due to an 
unpaired electron and highly detrimental to skeletal myocytes by promoting oxidative 
reactions with proteins, lipids, and DNA [319, 360-362].  
It is well established that ROS is abnormally increased in the CHF state [89, 
363]. Excessive ROS not only exacerbate the failing heart but also injure peripheral 
organs, such as skeletal muscle. Indeed, redox homeostasis is impaired in the skeletal 
muscle of CHF animals and excessive ROS accumulates, leading to contractile 
dysfunction and muscle atrophy, and the subsequent fatigue and exercise intolerance 
[364, 365]. In addition to pro-oxidant processes, one particular mechanism for underlying 
skeletal, myopathy in CHF is an impaired antioxidant defense system.  
Increasing evidence suggests that Nrf2 participates in the redox hemostasis of 
skeletal muscle and plays a critical role in skeletal muscle function. For instance, In 
cultured myocytes, electrical stimulation activated Nrf2 and upregulated antioxidant 
enzymes, which was abolished by Nrf2 siRNA[366]. In addition, the baseline expression 
of antioxidant enzymes in skeletal muscle of Nrf2 KO mice was significantly lower than 
WT mice [367]. An in situ study further demonstrated that the gastrocnemius of Nrf2 KO 
mice developed more rapid fatigue and less force generation as compared with the WT 
[368]. In the present study, we found that Nrf2 expression in Sol and EDL muscles was 
significantly lower in CHF mice as compared with Sham, suggesting that the above-
mentioned dysfunction of endogenous antioxidant defenses in skeletal muscle in CHF is, 
at least in part, due to impaired Nrf2 signaling. These CHF mice also displayed 
significantly decreased HO-1 and SOD2 expression as well. 
The balance between protein degradation and synthesis plays a crucial role in 
the maintenance of skeletal muscle mass[369]. Atrophy of skeletal muscle occurs when 
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protein degradation exceeds protein synthesis. In CHF, skeletal muscle breakdown, 
partially due to hyperactivated ubiquitin-proteasome system, play a dominant role in 
muscle wasting [370]. In skeletal muscle of CHF rats, two muscle-specific E3 ubiquitin 
ligases, MuRF-1 and atrogen-1, are upregulated [371]. Administration of bortezomib, a 
proteasome inhibitor, in CHF rats improves diaphragm function by restoring myosin 
content via suppressing MuRF-1/atrogen-1 expression and UPS activity [372]. 
Importantly, apocynin, an antioxidant reagent, normalized UPS activity and prevented 
skeletal muscle atrophy in CHF rats [364], suggesting a critical role of ROS in the UPS-
induced skeletal myopathy. In the present study, we found a significant increase in total 
ubiquitinated proteins, upregulated MuRF-1/atrogin-1, and downregulated 
myogenin/MyoD in the muscle of CHF mice, confirming the contribution of UPS to 
muscle atrophy in CHF state. We further found that these molecular alterations were 
attenuated and accompanied by an upregulated Nrf2 after Cur administration, 
suggesting Nrf2 as a potential therapeutic target of skeletal muscle atrophy in CHF.  
Exercise capacity tests revealed a significantly decreased maximal distance and 
speed in CHF mice as compared with sham. Overtime (from 12 to 20 weeks) post MI, 
exercise capacity progressively worsened in CHF mice, suggesting that skeletal muscle 
and/or cardiac function deteriorate over time. On the other hand, exercise capacity of 
CHF-Cur mice did not deteriorate over time and the speed and distance were 
significantly higher compared with CHF-Veh treated mice. These data suggest that Cur 
prevented the decline in the exercise capacity and/or cardiac dysfunction in the CHF 
state. Although Nrf2 was not evaluated in the heart, it is unlikely that Cur affects the 
heart as the cardiac function was not different among the groups. We believe that the 
enhanced exercise performance in CHF mice was driven primarily from the effect of Cur 
on the skeletal muscle. However, given the route of Cur administration, the effect of Cur 
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may extend beyond skeletal muscle and may include skeletal muscle microvasculature  
and neurons. To further support our conclusion of Cur effects on skeletal muscle, we 
performed a whole-body tension test, an in vivo technique to acutely evaluate skeletal 
muscle force with less influence from cardiopulmonary adjustments; this test showed 
that CHF-Cur treatment resulted in an increase in whole-body force as compared with 
CHF-Veh treatment. Furthermore, Cur enhanced exercise capacity in sham mice, 
suggesting that the beneficial effects of Cur are not exclusive to the CHF state.  
We further evaluated skeletal muscle force generation and fatigue resistance 
using an in situ muscle preparation. For the Sol muscle, there was no difference in the 
initial force (evoked by first tetanic stimulation) between CHF-Veh and Sham-Veh, 
whereas the later force (evoked by the 400th stimulation), in the CHF-Veh group was 
significantly reduced compared with Sham-Veh. For EDL, both the initial and late force 
were significantly reduced in the CHF-Veh group compared with the Sham-Veh group. 
These abnormalities were found to be ameliorated by Cur. These data suggest that both 
oxidative and glycolytic muscles from CHF mice exhibited reduced resistance to fatigue, 
a possible mechanism underlying exercise intolerance. Although the Sol muscle fibers in 
the CHF-Veh group exhibited a decreased CSA, the initial force production was not 
decreased compared with the Sham-Veh group. This may be due to the fact that we 
used a submaximal stimulation frequency (50 Hz), which could lead to a shift of the 
force-frequency relationship and therefore to similar forces in atrophic muscle. 
Curcumin has been shown to exerts antioxidant effects and protect mitochondria 
by activating the Nrf2 pathway [373].  A growing body of evidence indicates that Cur can 
limit skeletal muscle atrophy in several pathological conditions by enhancing antioxidant 
defense through stimulation of the Nrf2 signaling pathway [374, 375]. Furthermore, Cur 
also ameliorates exercise-induced fatigue and enhances exercise endurance in healthy 
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mice [376]. This is the first study, to the best of our knowledge, that evaluated the 
therapeutic potential of Cur in skeletal muscle in the CHF state. In the present study, we 
demonstrated that eight weeks of Cur treatment improves exercise performance, 
increases whole-body pulling force, and ameliorates skeletal myopathy in mice with 
CHF, suggesting a potential application for CHF-associated skeletal myopathy. Indeed, 
in patients with mitochondrial myopathy, a disease characterized skeletal muscle 
weakness and exercise intolerance, the Nrf2 activator, Omaveloxolone, lowered lactate 
production during submaximal exercise indicating an improvement in aerobic work 
capacity and submaximal exercise capacity [377]. This improvement in aerobic capacity 

































































Major Findings of the Dissertation 
 
 
The major findings of this dissertation are: 
1. Nrf2 protein is down-regulated in the RVLM of mice with CHF, which was 
associated with enhanced sympathetic nerve activity.  
2. Exercise training attenuated the reduction of Nrf2 in the RVLM of CHF mice, 
which was associated with reduced sympathetic nerve activity.   
3. Nrf2 protein is reduced in the skeletal muscle of CHF mice, which contributes to 
skeletal myopathy and exercise intolerance.  
4.  Curcumin upregulates Nrf2 in skeletal muscle of mice with CHF, which was 
associated with improved exercise performance.  
In addition to these major findings, we have provided supporting evidence for the 
previously observed reduction of Nrf2 in the RVLM post-MI [294]. We have also 
demonstrated that reduced Nrf2 signaling in the RVLM and skeletal muscle of CHF 
mice was associated with downregulation of major antioxidant enzymes, confirming 
the role of Nrf2 as a master regulator of phase II antioxidant enzymes. Given the 
previous studies from our and other labs that demonstrate the key mechanistic role 
of Nrf2 in mediating the expression of antioxidant enzymes in both RVLM  [132, 294] 
and skeletal muscle [378], it is likely that Nrf2 mediates the increase in antioxidant 
enzymes in the RVLM and skeletal muscle of mice with CHF in response to ExT and 
Cur treatment.  
 Taken together, these findings indicate that Nrf2 upregulation represents a key 
link and mechanism in response to ExT and Cur treatment and enhanced 
antioxidant defense in the RVLM and skeletal muscle of mice with CHF. These 
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studies represent the genesis of a holistic approach against increased oxidative 
stress in the CHF state. 
 
Objectives 1-2: Nrf2 and ExT 
 Because downregulated antioxidant enzymes contribute, in part, to an increased 
ROS in the RVLM, and given the role of an increased ROS in modulating ion channels 
and enhanced sensitivity of presympathetic neurons [113, 144, 379], it is likely that 
reduced expression of Nrf2 in the RVLM contributes to the sympathoexcitation in CHF 
observed in this study. Since Nrf2 upregulation in the RVLM of mice with CHF 
attenuates sympathoexcitation [294], and because in this study, ExT attenuated Nrf2 
reduction in CHF mice, ExT-induced reduction of sympathoexcitation in CHF in this 
study is likely Nrf2 dependent. The precise contribution of Nrf2 to sympathoexcitation in 
response to ExT would greatly increase our ability to draw conclusions regarding the role 
of Nrf2 in this pathway. These experiments, although started, were not completed due to 
the slow pace of Nrf2 floxed mouse breeding and separation into CRE treated and GFP 
treated Sed and ExT groups.  
 The fact that ExT did not improve cardiac function in mice with CHF should not 
be unexpected. Although ExT is beneficial for patients with CHF [380, 381], the majority 
of existing evidence suggests that Ext in the CHF state improves quality of life and 
reduces mortality [382], but does not positively affect cardiac function per se [383].  
Previous work from this laboratory suggests that ExT has no influence on cardiac 
function[133, 384, 385] and that the more severe CHF, the less likely it is to improve 
cardiac function by ExT. The present study clearly showed that ExT increased work 
performance in CHF mice, an exercise adaptation likely mediated by peripheral 
adaptations rather than cardiac functional improvement. 
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Despite the fact that ExT had no effect on cardiac function (e.g. EF), correlative 
data that relate to RVLM Nrf2 expression as a function of heart failure severity were 
independent of the sedentary or exercise status of animals. We believe that these data 
depict a continuum of antioxidant regulation in sympathetic neurons that is driven, in 
part, by cardiac function (e.g. cardiac output). The heart, along with kidney, account for 
62% of the increase in total plasma NE in CHF patients [386]. This increase In the 
sympathetic drive to the heart is not only detrimental and associated with reduced 
survival, but also correlates negatively with cardiac function [387].  
The fact that the CS was only modestly increased in Sham-ExT does not, in our 
opinion, reflect a poor exercise adaptative response. Citrate Synthase is just one 
indicator and is dependent on mitochondrial function [292]. It is also possible that mice in 
this group (Sham-ExT) were not stressed enough (low exercise intensity). Ideally, ExT 
intensity is determined based on maximal oxygen consumption (VO2max). Because the 
relationship between running speed and oxygen uptake is linear [388], we utilized 
maximum running speed as a surrogate for maximal oxygen uptake.  
As mentioned previously, clearly one of the major limitations in this study is the 
lack of evaluation of and direct measurement of oxidative stress. However, as mentioned 
in chapter II, our lab has published several papers showing 1. that up and down 
regulating Nrf2 in the RVLM of both normal and heart failure animals results in an 
inverse relationship between oxidative stress and Nrf2/antioxidant enzyme expression 
[294] and 2. that exercise training reduces oxidative stress in the RVLM of CHF animals 
[133, 308]. Another limitation is that only NQO-1 was measured in the exercise study, 
despite the fact that there are dozens of Nrf2 regulated genes. Our lab has previously 
shown that ExT upregulates several antioxidant enzymes in the RVLM of CHF animals 
[133]. Therefore, especially with the small amount of protein extracted from the RVLM in 
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mice, we felt it is unnecessary in this study to measure additional proteins to make our 
point that the relationship between Nrf2 and antioxidant enzyme expression is altered by 
ExT in heart failure. 
Future directions 
 Future work will be important in expanding our understanding of the observations 
in this study. Although we believe our studies have made an important contribution to the 
field, numerous studies are required to further understand the role of central Nrf2 in 
mediating the beneficial effects of ExT with regard to sympathetic nerve activity. Both in 
vivo CHF models and cellular/molecular studies are required to closely investigate the 
role of Nrf2 in the RVLM in modulating sympathetic nerve activity in response to ExT.  
 An important question to be addressed is what mechanisms, other than reduced 
transcription, contribute to the reduced Nrf2 level in the RVLM? In this regard, enhanced 
Nrf2 ubiquitination is a possible mechanism thus, co-immunoprecipitation experiments 
are required. Other mechanisms for the reduced Nrf2 expression in the RVLM in the 
CHF state involves NFkB. Both Nrf2 and NFkB are ROS-sensitive transcription factors, 
and both have been shown to bind to the CBP in the nucleus[252]. Due to enhanced 
AT1R signaling (known to occur in CHF), ROS generation, and cytokine/inflammatory 
signaling [389] it is possible that increased NFkB reduces the ability of Nrf2 to bind to the 
CBP in the nucleus. Given the increased Nrf2 protein in the RVLM after ExT, it is 
possible that ExT reduces Nrf2 ubiquitination, reduces NFkB, and increases Nrf2 binding 
to the CBP. Finally, it is possible that Nrf2 translation is regulated by changes in specific 
microRNAs (e.g. 27a, 28a and 34) that are overexpressed in CHF and may be reduced 
by ExT. In this regard, our laboratory has recently shown both local and remote 
regulation of Nrf2 by these specific microRNAs in CHF [248, 390]. 
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 Another question to be addressed in the future is whether ExT lowers 
sympathetic nerve activity primarily or exclusively through a Nrf2-dependent mechanism. 
Using animals where Nrf2 in the RVLM is deleted, it should be possible to evaluate 
whether ExT has effects on oxidative stress, antioxidant enzymes, and sympathetic 
nerve activity. 
 Increased ROS represents a link between ExT and Nrf2 activation [258]. An 
important concept that needs to be addressed is the specific ROS involved in mediating 
Nrf2 activation. To evaluate specific ROS that stimulate Nrf2 in response to ExT, one 
strategy would be to virally transfect pre-sympathetic neurons with SOD or catalase in 
CHF mice. For example, urine or plasma NE and RSNA after ExT could be measured to 
evaluate if they are associated with increased or reduced Nrf2 in the RVLM. On the 
other hand, because catalase is localized to the peroxisome, viral expression of catalase 
may not prove that H2O2 is not involved in Nrf2 activation. Therefore, additional studies 
using other H2O2 removal enzymes localized in other places in the cells such as 
glutathione peroxidase, thioredoxin peroxidase, and peroxiredoxin are required to 
address the role of H2O2 in Nrf2 activation in response to ExT.  
 In the present study, we evaluated plasma and urinary NE as an index of 
increased sympathetic nerve activity in CHF. These measurements provide information 
regarding the sympathetic nerve activity in mice; however, measuring sympathetic nerve 
activity directly by electrophysiological techniques will provide better and more 
convincing evidence of sympathoexcitation. This unfortunately was not done in this 
study. Other studies from our lab have clearly shown an increase in RSNA in both 
animals in the heart failure state and a decrease following exercise training [391] [133]. 
Furthermore, a randomized clinical trial demonstrated that ExT markedly reduced 
muscle sympathetic nerve activity (measured by peroneal nerve recording) [153]. 
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Objectives 3-4: Curcumin, Nrf2 and exercise intolerance 
 
Perhaps, the biggest concern about Cur is its limited bioavailability. Rodents 
have been treated with Cur at doses reported to range from 10 to 1000 mg/kg/day. The 
dose used in the present study was chosen based on previous studies [376, 392], in 
which the Cur dose of 50 mg/kg/day was effective in improving skeletal muscle function 
and exercise performance in mice. To provide a context for this dose, a dose of 20 
mg/kg/day equates to approximately 4 mg/kg/day in humans based on the guide for 
dose conversion between animals and humans by Nair and Jacob [393]. This dose has 
been employed in clinical trials to treat cancer and inflammatory diseases [394]. 
Because of poor oral bioavailability of curcumin [270, 273], and because 8 weeks of ip 
injections would impose undue stress, we chose to deliver Cur by osmotic minipump. 
While we did not measure Cur biodistribution, a previous study [395] has shown that 
plasma Cur concentrations were 0.127 ± 0.035 and 0.238 ± 0.048 ug/ml at 4 hours after 
administration of 148 ug i.p. and 74 ug i.m., respectively. Plasma levels of Cur were not 
detectable when 148 ug curcumin was administered by oral gavage. Given the effects of 
Cur on exercise performance and skeletal myopathy, we believe that the dose (50 
mg/kg/day) was adequate. 
 Despite the fact that Cur fully rescued Nrf2 and downstream targets, it only had a 
small restorative effect on skeletal muscle performance but prevented the deterioration 
of exercise performance in CHF state. These findings suggest that other mechanisms 
are involved in exercise intolerance in CHF. Indeed, in addition to skeletal myopathy, 
cardiovascular and pulmonary dysfunction also contribute to exercise intolerance 
associated with CHF [193, 352] 
The concept of skeletal muscle atrophy in CHF is disputed. Some studies [195, 396] 
indicate that exercise intolerance in CHF is associated with atrophy, but not in all studies 
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[397, 398] confirm this idea. One possible explanation for this discrepancy is that 
skeletal muscle atrophy usually emerges in advanced CHF (class III-IV). Although the 
mice in this study have more advanced CHF (perhaps mimicking class III-IV), we did not 
observe a significant difference in body weight or soleus muscle weight, although there 
was a trend for lower body weight in CHF mice. This may be due to the fact that muscle 
atrophy is more a consequence of deconditioning or disuse [190].  
Future directions 
 The present study suggests that Nrf2 is likely a mechanism by which Cur 
prevents the decline in exercise performance in CHF. To further support a mechanistic 
role of Nrf2, experiments need to be carried out in muscle-specific Nrf2 knockout mice. 
For example, the effect of Cur on skeletal muscle and exercise performance could be 
examined in inducible muscle-specific Nrf2 floxed mice (as iMS-Nrf2flox/flox) with the 
speculation that the beneficial effects of Cur on skeletal muscle antioxidant defense and 
exercise performance will be blunted after deletion of the Nrf2 gene. 
Age and gender issues 
 Males and females exhibit a different risk for CHF. Evidence suggests that Nrf2 
activation may be different between males and females[399]. Both age and gender of 
the mice used in this study represent a limitation in translating this work to humans. 
However, using older animals is problematic in a study like this because aging, by itself, 
is associated with increased ROS levels in the brain [400] and in skeletal muscle [401]. 
Thus, it would be difficult, perhaps impossible, to separate CHF from aging. We could 




Synergic effects of exercise training and curcumin  
Recent work has demonstrated that there is a potential synergetic effect of 
combining ExT with known Nrf2 activators. For instance, synergetic effects between 
Coenzyme Q10 and ExT, independent of each other, significantly increased Nrf2 
expression in heart, liver, and skeletal muscle. [264]. Furthermore, Nrf2 activation 
concurrent with ExT increased swimming endurance compared with ExT alone[261]. 
However, as mentioned in the previous sections, Cur is not only an activator for Nrf2, but 
it also has a direct antioxidant property, which may interfere with ROS-induced signal 
adaptation. Indeed, randomized controlled trials have shown that the health-promoting 
effects of exercise such as insulin sensitivity and antioxidant defense capacity were 
blocked by concurrent supplementation with Vitamins C and E [402, 403]  
 
Conclusion and Perspectives 
The major findings of this dissertation are summarized in figure 4.1. The primary 
aim of this dissertation was focused on the role of Nrf2 as a potential mediator of 
sympathoexcitation (objective 1) and exercise intolerance (objective 3). Furthermore, the 
dissertation was also focused on the role of Nrf2 in the RVLM as a potential link between 
the act of ExT and a change in autonomic activity (objective 2), as well as a link between 
antioxidant enzymes and exercise performance in response to Cur administration 
(objective 4). CHF is a sympathoxcitatory state associated with high mortality. In 
addition, exercise intolerance is a cardinal symptom of CHF that profoundly impacts 
patient’s quality of life. Ultimately, the goal of any treatment is to either improve survival 
and/or improve quality of life. Although the results of the experiments in the present 
study cannot be extended directly to the clinical field, the data in this study provide new 
information with regard to the beneficial effects of ExT and antioxidant therapy in CHF.  
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 Optimal medical therapy for CHF clearly has a profound beneficial effect with 
regard to the long-term outcomes. For instance, ACE inhibitors, AT1R blockers, and ß1-
adrenergic blockers reduce morbidity and mortality, however their effect on exercise 
tolerance remains questionable  [404-406]. Thus, these medications, although essential, 
cannot be considered as a surrogate for ExT, which is associated with peripheral 
adaptations such as increased peripheral blood flow, O2 delivery, oxidative capacity, and 
increased muscle mass. These effects are translated into an increase in VO2 max, which 
is associated with improved survival and better quality of life. An increase in VO2 max by 
1 ml/min/kg is associated with a 9% reduction in all-cause mortality [407]. In addition, 
because exercise intolerance in CHF is directly related to skeletal muscle abnormalities, 
specific therapy targeting these abnormalities is important.  
 The interplay between the objectives of this dissertation supports the concept 































Figure 4.1 – Summary of the major findings in the dissertation  
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